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Abstract
Cancer cachexia is a multifactorial wasting syndrome characterized by losses in body
mass >5% and occurs in approximately 80% of all cancer patients. Chronic inflammation and
fibrosis play roles in cancer cachexia and a greater understanding of these contributing pathways
to this pathology will pave the way for potential therapeutic avenues. While inflammation and
fibrosis have been researched in various models of cancer cachexia, little to no studies have been
performed in both sexes as most previous studies focus on males. PURPOSE The purpose of
these studies is to investigate the role of fibrosis on cancer cachexia development as well as the
effects of leucine supplementation on cancer cachexia in both sexes. METHODS Lewis Lung
Carcinoma cells (LLC) or PBS (control) were injected into the hind-flank of C57Bl6/J mice at 8
wks age, and tumor allowed to develop for 1, 2, 3 or 4 wks. WT and APCMin/+ mice were
supplemented with regular or leucine-enriched water following weaning up until euthanasia at 20
weeks of age. Body and pertinent tissue and muscle weights were taken. Histology was used to
measure CSA. RT-qPCR and immunoblotting were used for analysis of markers of fibrosis in the
LLC study, and markers for inflammation, protein anabolism and catabolism, and myogenesis in
the APC study. RESULTS Both male and female LLC mice exhibited increased fibrosis at the
onset of cancer cachexia. Females, however, saw induction of pro-fibrotic markers such as TGFβ and Collagens 1 and 3 as early as 1wk post-injection when compared to males who saw no
increases until 4wks when cachexia was developed. Male APCMin/+ mice had greater reductions
in body weight following leucine supplementation whereas female APCMin/+ mice did not
experience this effect of leucine. Higher elevation of IL-6 mRNA abundance accompanied the
decrease in body weight in male APCMin/+ mice. Myogenesis was altered in female mice,
favoring satellite cell activation and differentiation with increases in MyoD and Myogenin over

quiescence. Myotube diameter was decreased following addition of blood plasma taken from
male APCMin/+ mice. DISCUSSION Fibrosis clearly plays an early role in the development of
cancer cachexia through upregulation of the TGF-β pathway, but timing of TGF-β and collagen
induction differed between sexes. However, the canonical effectors downstream of TGF-β were
not altered in either sex in the LLC time course. Supplementation of leucine exacerbated cancer
cachexia in male but not female APCMin/+ mice, and elevation of inflammatory IL-6 accompanied
this effect of leucine. Altered myogenesis in females suggests a protective effect from wasting in
female mice and could explain the lack of reduction in myotube diameter observed in APCMin/+
female plasma treated cells. These data provide novel insight into variations in fibrosis as well as
responses to nutraceutical interventions for cancer cachexia between sexes.
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Chapter 1
Introduction
Cancer is a leading cause of death worldwide according to the World Health
Organization (WHO), with estimations of upwards to 9.6 million deaths in 2018. In the U.S.
alone, it is estimated ~600,000 people perished as a result of cancer in the year 2020, and
according to the Center for Disease Control (CDC) ~39% of all men and women acquire some
form of cancer in their lifetime [1, 2]. While the causes and severity of cancer has been well
documented what is less understood is the concurrent wasting of muscle mass that a large portion
of cancer patients can experience, otherwise known as cancer cachexia. Cancer cachexia is a
multi-factorial wasting syndrome of skeletal muscle, which can be accompanied with or without
losses in fat mass and worsens cancer patient health and ultimately outcomes [3]. Cancer
cachexia is defined by losses of body mass >5% and occurs in ~80% of all cancer patients [4, 5].
Cancer cachexia is directly responsible for ~20% of cancer deaths, and therefore affects most
cancer patients to at least some extent [4, 5, 6]. Of growing concern in cancer research is the
apparent divergence in cancer severity and response to cancer treatments that occurs as it relates
to differences in sex [7, 8, 9]. These sex differences create an added layer of difficulty to
properly evaluate and subsequently create ubiquitously effective treatments, and thus require
elucidation with regards to treating cancer cachexia and its associated complications. Creating a
better understanding of cancer cachexia and treatment options that can help alleviate its severity
in both sexes provides a substantial opportunity to improve and potentially save cancer patient
lives on a global scale.
The multifactorial nature of cancer cachexia has resulted in a multifaceted approach to
investigate and treat the underlying causes of lean tissue wasting. Of note, a dysregulation in
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protein turnover observed in cachectic cancer patients has led to research investigating
nutraceutical interventions to help improve protein anabolism and reduce the catabolic state of
these patients [10, 11, 12, 13]. However, none to date have proven effective at alleviating the
symptomatic wasting of muscle mass during cancer progression thus creating a need for further
evaluation as to why this is the case. Also associated with wasting of skeletal muscle due to
cancer is the development of increased fibrosis and replacement of healthy tissue with noncontractile fibrotic proteins [14, 15, 16]. Deposition of collagen and related extracellular matrix
components in skeletal muscle further exacerbates muscle mass losses thereby worsening the
cachectic phenotype in cancer patients. A thorough evaluation across both sexes of anabolic
nutraceuticals and the role fibrosis plays on cancer cachexia could create potential therapeutic
avenues for cancer cachexia treatments. This literature review will outline research that has
shaped what we currently understand concerning cancer cachexia, nutraceutical interventions
against cancer cachexia and muscle wasting, and the role fibrosis can play in cancer cachexia
progression.
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Review of Literature
Cancer Cachexia Physiology
Cancer cachexia affects a large portion of the cancer population and results in worsened
patient health and mortality rates [17, 18]. Interventions targeting the root causes of cachexia
progression have yet to yield effective improvements in skeletal muscle maintenance. Many of
the key regulators of cancer cachexia are processes that influence the regulation of muscle mass,
such as inflammation, protein turnover, atrophy, autophagy, and myogenesis [4, 13, 19, 20, 21].
Understanding these cellular processes within cancer cachexia and the role that sex differences
can play on each is vital for future treatments.
A. IL-6 and Inflammation
Inflammation is a known instigator of cachexia progression when allowed to exceed
healthy levels and possesses a profound systemic effect on skeletal muscle wasting [22]. Largely,
the main contributors to this systemic induction of cachexia are pro-inflammatory cytokines such
IL-6, IL-1. IL-8, TNF-α, and IFNγ [17]. Inhibition of these pro-inflammatory cytokines, namely
IL-6, has shown improvements on skeletal muscle wasting [23, 24]. Due to strong link IL-6 has
on inflammation regulation and ultimately cancer cachexia, evaluating IL-6 and how its
elevation influences skeletal muscle wasting has been a great topic of research since its link to
cancer cachexia was discovered [21, 23, 25-30]. Typically, IL-6 plasma concentration will
increase following tumor formation and this increase can continue to extreme levels as cancers
progress [25]. IL-6 has been shown to reduce protein synthesis via downstream inhibition of
mTOR activity [31], potentially through the activation of AMPK [29]. JAK/STAT3 activation
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has also been linked to cancer cachectic wasting in C2C12 myotubes, and inhibition of AMPK and
STAT3 reversed the associated wasting in those same myotubes [29].
TNF-α is another potent cytokine shown to be elevated in cancer patients that can directly
influence protein degradation through degradative processes such as the ubiquitin proteasome
system (UPS), while simultaneously inhibiting protein synthesis similarly to IL-6 [27, 32]. TNFα can activate NFκB to translocate to the cell nucleus and induce the transcription of E3 ligases
and atrophy-related genes, also known as atrogenes [33, 34], such as Atrogin-1 and MuRF-1
[35]. Induction of the UPS and these related pathways will result in excessive tagging of proteins
for degradation via the proteasome. Upregulation of E3 ligases and subsequent proteolytic
degradation further exacerbates skeletal muscle wasting in cancer cachexia.
B. Protein Synthesis

Fig 1-1. Flow chart depicting the role of protein
turnover on cancer cachexia.
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Imbalances in protein turnover in cancer cachexia patients is noted by dysregulation in
protein anabolism compared to protein catabolism [36, 37, 38]. This imbalance leads to overall
losses in muscle mass as proteins are being broken down at a greater rate than can be synthesized
[39, 40] (Figure 1-1). The synthesis of proteins is a tightly regulated process that ultimately is
controlled through successful formation of the ribosomal complex for translation of mRNA into
proteins. Formation of the ribosomal complex begins with formation of the 43S pre-initiation
complex by binding of the 40S ribosomal subunit to the initiator methionyl-tRNA in order to
initiate translation [41]. Next, the eIF4F complex containing eIF4E (cap-binding protein), eIF4G
(scaffold protein), and eIF4A (ATP-dependent mRNA helicase) can then combine with the 43S
pre-initiation complex to form the 48S ribosomal complex [41, 42]. The formation of the eIF4F
complex is the rate-limiting step for initiation and control of protein synthesis, where eIF4E capbinding protein is sequestered by 4E-BPs, namely 4E-BP1, and only hyper-phosphorylation will
release eIF4E from 4E-BP1[43, 44]. As such, analysis of the 4E-BP1 and its upstream signaling
cascade have aided analyses aimed towards understanding fluctuations in protein synthesis.
Mechanistic target of rapamycin (mTOR) is the major regulator upstream of 4E-BP1,
where mTOR aids in hyper-phosphorylation of 4E-BP1 and phosphorylation of ribosomal
protein S6 kinase beta-1 (p70S6k) to promote translation initiation and greater production of
proteins [45]. mTOR activity is known to be suppressed in cancer cachectic patients and mice,
but the effects of various treatments targeting this protein synthesis pathway have not been
completely elucidated [46, 47, 48]. 5' AMP-activated protein kinase also emerged a potent
mediator of protein synthesis due to its capability to interact with and inhibit mTOR’s effect to
activate its downstream effectors of protein synthesis p70S6k and 4E-BP1 [47]. Recent studies
have supported this by reporting elevated AMPK levels in association with cancer cachexia, and
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this has commonly been in conjunction with altered mTOR activity [47, 49]. Understanding the
role of protein anabolism as it relates to cancer cachexia and potential treatments to improve
protein anabolism likely is critical to alleviate muscle wasting.
C. Atrophy
Muscle atrophy due to cancer cachexia progression relates to processes of protein
degradation elevated to a greater extent than processes related to protein synthesis. The UPS is
known to be upregulated in various models of muscle atrophy, especially in cancer cachexia [50,
51]. The proteasome plays a pivotal role in the breakdown of proteins tagged for degradation via
ubiquitin tagging, and within the correct balance is necessary for the healthy removal of proteins
[52, 53]. But at chronically elevated or even extreme levels as seen in cachectic patients the UPS
results in excessive protein breakdown and ultimately muscle wasting.
The proteasome consists of two subunits, the catalytic core 20S subunit and the
regulatory 19S subunit [53]. Combined these two subunits create a complete a functional 26S
proteasome complex that will actively destroy proteins that have been labeled with ubiquitin tags

Fig 1-2. Ubiquitin Proteasome System (UPS).
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[53, 54] (Fig 2). The process of ubiquitination revolves around three series of ubiquitin labeling
enzymes: 1) ubiquitin-activating enzymes (E1), 2) ubiquitin-conjugating enzymes (E2), and 3)
ubiquitin-protein ligases (E3) [53, 55]. The third step of ubiquitination involving the E3 ligases
has become a valuable part of measuring relative levels of proteolysis in wasting diseases such as
disuse, anorexia, and cancer cachexia [55, 56]. E3 ligases such as Muscle Atrophy F-box
Protein-1(Atrogin-1) and Muscle Specific RING Finger-1 (MuRF-1) have been the focus of
muscle wasting research, where increased transcription of these genes has been positively
correlated with worsened muscle wasting [57, 58]. Atrogin-1 and MuRF-1 are primarily
regulated by the FOXO-1 and FOXO-3 transcription factors, where upon their activation both
FOXO-1/3 translocate to the nucleus of the cell and directly aid in transcription of Atrogin-1 and
MuRF-1[53, 55, 59]. Therefore, evaluating the activation of FOXO-1 and FOXO-3 as well as
their downstream transcriptional products in the form of Atrogin-1 and MuRF-1 can create a
better understanding of relative proteolytic activity in wasting pathologies.
The FOXO1/3 family of transcription factors is regulated via the Protein Kinase B (from
here on out known as AKT) pathway, where AKT phosphorylates FOXO1/3 and inactivates their
transcriptional capability [60]. Due to AKT’s prominent role in protein synthesis by its ability to
activate mTOR, relative activity of these protein synthetic markers would then play a role in
regulating proteolytic activity via Atrogin-1 and MuRF-1. Cytokines such as IL-6 also aid in
upregulation of Atrogin-1 and MuRF-1 in cancer cachexia [61, 62]. Due to the intertwined
relationship between inflammatory and protein synthetic pathways on proteolytic activity,
evaluating all three in conjunction yields the greatest value in understanding the role of
proteolysis on cancer cachexia.
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D. Autophagy
Autophagy, like the proteasome, is necessary for health destruction and removal of
proteins but is also found to be dysregulated in cancer cachexia [63, 64]. Autophagy is induced
in times of nutrient deficiency, oxidative stress, or reduced energy and is negatively impacted
when protein synthesis levels are high as activation of mTOR inactivates autophagy mechanisms
[65, 66]. Autophagy is the process of producing an autophagosome to induce the destruction of
cellular proteins and even organelles for recycling of their components in times of cellular stress.
Autophagy is initiated via the formation of a phagophore or nucleation membrane. The
phagophore is elongated, resulting in a nascent autophagosome, which then can engulf proteins
that are marked for degradation and is now considered mature. Finally, the mature
autophagosome fuses with lysosomes, resulting in autolysosomes, and consumed contents are
degraded via catalytic enzymes. Prominent markers associated with autophagosomal degradation
of proteins are autophagosome membrane-associated LC3 I and LC3 II, and p62/sequestosome 1
(SQSTM1) [67, 68]. LC3 I is the cytosolic form which is then converted to LC3 II during
lengthening of the phagophore to form the autophagosome. p62 interacts and sequesters
ubiquitinated proteins to the autophagosome for degradation via autophagy as opposed to via the
proteasome [69-71]. Impaired autophagy appears to occur in conjunction with cancer cachexia
progression and may result in mitochondrial dysfunctions as well if damaged mitochondria and
their cellular components are not successfully recycled [63, 72, 73]. Due to its related nature of
breaking down ubiquitinated proteins similar to the proteasome, measuring autophagic markers
in combination with proteasomal ones can create a comprehensive picture of protein degradation
in cancer cachexia.
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E. Myogenesis
Myogenesis, or the development and regeneration of skeletal muscle tissue, is necessary
for healthy skeletal muscle regeneration and maintenance. The myogenic process can be divided
into three major stages of 1) Activation, 2) Proliferation and 3) Differentiation. Prior to
activation a muscle damaging stimulus such as exercise or pathological conditions induces the
myogenic process to begin in order to prevent muscle loss [74, 75]. Next muscle is infiltrated by
neutrophils and then macrophages which breakdown damaged or necrotic tissue, as well as
releasing potent growth factors such as vascular endothelial growth factor (VEGF), platelet‐
derived growth factor (PDGF), insulin‐like growth factor (IGF) and hepatocyte growth factor
(HGF) [74-76]. These growth factors aid in activation of resident and quiescent satellite cells to
begin the process of forming new myoblasts. While quiescent, satellite cells expressed the Paired
box protein (Pax7) and no MyoD [76-79]. However, once activated by these growth factors,
satellite cells switch towards greater MyoD expression in order to enter the cell cycle and
multiply into more myoblasts known as the Proliferation stage [76-79]. Finally, Pax7 expression
decreases and satellite cells express Myogenin where they then differentiate into myotubes and
fuse at the site of injury to regenerate damaged myofibers [76-79]. The myogenic process has
been shown to be impaired in vitro and in vivo [80, 81], but recently literature has aimed to
understand what alterations in the myogenic process are involved with cancer cachexia
progression. Most recent evidence ties the chronic elevation of inflammatory cytokines such as
TNF-α, NFκB and IL-6 to alterations in key myogenic regulators such as Pax7 and MyoD [8284]. Chronic overexpression of Pax7 in conjunction with NFκB has been observed in cachectic
mice to the extent where satellite cell activation is impaired and therefore downstream
proliferation and differentiation result in incomplete myogenesis and worsened muscle atrophy
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[82-84]. These negative alterations and the role they play on myogenesis in cancer cachexia is
necessary to determine to what extent impaired myogenesis correlates to cancer cachexia
progression.
Nutraceutical Interventions for Cancer Cachexia
A. Current literature
Because cancer cachexia is marked by its irreversible losses in skeletal muscle mass a
great deal of research has focused on alleviating this chronic wasting by use of nutritional and
nutraceutical interventions. More specifically, attempts to improve caloric intake and evaluation
of nutraceuticals aimed at alleviating cancer cachexia associated dysfunctions have been the
main focus. Reduced appetite has been known to contribute to cancer cachexia progression as it
results in reduced caloric intake [85, 86], however interventions aimed at solely improving
calorie consumption have not effectively alleviated cancer cachexia associated wasting [85, 87,
88]. Nutraceuticals have the ability to target one or several cellular processes in such as protein
synthesis or inflammation in an effort to improve each’s effect on cancer cachexia progression
[89-92]. Long-chain omega-3 fatty acid eicosapentaenoic acid (EPA) is one such nutraceutical
that is known to improve inflammation by reducing NFκB expression and has been supported to
improve muscle wasting in smaller human studies [93, 94, 95], but these findings were not
supported in studies of larger sampling [96, 97]. Quercetin is another anti-inflammatory targeting
nutraceutical that has been shown to improve and reduce IL-6 expression in APCMin/+ mice [11,
98, 99]. Other nutraceuticals such as β-hydroxy-β-methylbutyrate (HMB) have been used in
cachectic subjects for their ability to improve activation of protein synthesis markers such as
mTOR and AKT with successful implications on cancer cachexia [100, 101]. In fact, HMB
serves an example of a nutraceutical with the potential capability to improve markers of protein
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synthesis and atrophic regulators such as FOXO1/3 and MuRF-1 [100-104]. Following years of
research, no single nutraceutical has proven effective at alleviating cancer cachexia across all
populations. In all likelihood a multi-targeted approach of a nutritional/nutraceutical along with
additional interventions may be necessary to maximize anti-cachectic effects. In order to better
understand what a multi-targeted approach for cancer cachexia should look like, a thorough
evaluation of potential nutraceuticals on cancer cachexia is still required.
B. Leucine
Leucine is an essential amino acid and
one of three branch chain amino acids
(BCAA), along with iso-leucine and valine.
Leucine is most notable of the BCAA for its
capability to induce protein synthesis
machinery in skeletal muscle via direct

Fig 1-3. Leucine’s role on protein
synthesis in skeletal muscle.

activation of mTOR [105-107]. Increases in protein synthesis have a protective effect on skeletal
muscle from elevated protein catabolism which is observed across muscle wasting pathologies.
Due to leucine’s ability to stimulate mTOR it has been widely researched in skeletal muscle
across different exercise and pathological conditions such as cancer cachexia [108-112].
Depending on the model of cancer cachexia being used and other experimental conditions
leucine supplementation has shown either no improvements or marked improvements in protein
synthesis and preservations in muscle mass [113]. Low doses of leucine supplementation in
Lewis Lung Carcinoma (LLC) has shown no significant improvements in protein synthesis but
did lead to greater expression of Peroxisome proliferator-activated receptor gamma coactivator
1-alpha (PGC-1α) a known regulator mitochondrial biogenesis [114]. Cruz et al. reported that a
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leucine-rich diet resulted in improved muscle mass and protein content, but they contributed this
effect to reduced pro-inflammatory and greater anti-inflammatory signaling [115]. Leucine
supplementation has even shown improvements on proteasomal and lysosomal degradation in
tumor-bearing rats, but the exact mechanism as to how was not elucidated [115]. Research by
Baptista et al. suggests that leucine can reduce Atrogin-1 and MuRF-1 activity but is dependent
on its ability to suppress FOXO 3 upstream of both atrogenes, as supported by their in vitro
inhibition of leucine activity [116, 117]. Leucine dosage of 1.5% per volume has been reported
in previous studies to stimulate markers of protein synthesis while having no impact on
metabolic rates and has been widely utilized in leucine supplementation studies for that very
reason [145, 146, 147]. These variations in effect and efficacy reveal the need for further
evaluation of leucine supplementation and the underlying mechanisms that can contribute to any
and all improvements on protein synthesis and cancer cachexia.
Fibrosis in Cancer Cachexia
A. Extracellular matrix (ECM)
The ECM was thought for many years to act as a scaffold within skeletal muscle to allow
for proper anchoring and force production, but now we understand a great deal of the necessity
and complex role the ECM plays in overall skeletal muscle health. The ECM has three major
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layers within skeletal muscle starting with the epimysium surrounding the entire muscle, the
perimysium surrounds muscle fiber bundles that
comprise an entire muscle, and lastly the
endomysium that surrounds individual muscle
fibers [118]. The ECM itself accounts for ~5% of
the dry weight of skeletal muscle [76]. One major
key element of the ECM is that it surrounds the
Fig 1-4. ECM structure in skeletal
muscle

satellite cells responsible for skeletal muscle
growth and regeneration. As such, the ECM

maintains skeletal muscle structure and the crucial progenitor cells that manipulate myogenesis
[76, 119]. The ECM is also the host to growth factors such as transforming growth factor-beta
(TGF-β) that can aid in activation of satellite cells and downstream myogenic processes [76,
120]. Degradation or damage of the ECM results in release of these growth factors which can
now exert their effects to satellite cells and aid in regeneration [76, 119]. This capability of the
ECM to aid in repair and maintenance of skeletal muscle makes it critical for overall skeletal
muscle health. However, the ECM can also negatively impact skeletal muscle if there is excess
deposition of ECM components within skeletal muscle, a process known as fibrosis [14, 120].
Excessive fibrosis of skeletal muscle essentially replaces health skeletal muscle tissue with noncontractile and stiff ECM components. Fibrosis development can be traced back to persistent
inflammation and as a result is prevalent in models of cancer cachexia [121]. TGF-β is controlled
by inflammatory machinery such as IL-6 and is found to be upregulated in cancer cachexia,
resulting in continuous accumulation of ECM components such as Collagens and worsening
losses of skeletal muscle in cancer cachexia [15].
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B. Collagens, MMPs and TIMPs
Collagen comprises the majority of the ECM. There are over 28 known types of
Collagens all with varying characteristics and functions [122]. But within the skeletal muscle
ECM, Collagens I and III are the most abundant components with polarizing characteristics. Of
all the Collagens, Collagens I, II, and III make up over 90% of all Collagen in the body [123,
124]. All Collagens have a base structure revolving around a triple helix: two α1 chains and one
α2 chain. Each chain consists of ~1050 amino acids, with the majority of those amino acids
consisting of glycine, proline, and hydroxyproline. The repeating motif of this amino acid
arrangement is Gly-Pro-X, where X can be any amino acid. This repeating but still customizable
motif is what gives Collagen fibers similar and still unique forms and characteristics. Collagen 1
has more rigid and tensile characteristics, is pound-for-pound stronger than steel, and as such is a
crucial component in tendons [76, 124]. Collagen III has received less attention in research than
Collagen I as Collagen I is more readily isolated and extracted. Collagen III is a thinner, elastic
collagen and as such is more malleable under stressful conditions [76, 124]. Due to the opposing
characteristics of these collagens and their abundance within the skeletal muscle ECM recent
research has sought to compare the relative expression of Collagen I and Collagen III [125-127].
Creation of this Collagen ratio would then give insights into the rigidity or elasticity of the ECM.
The results of this ratio as it pertains to amounts of fibrotic material present together would aid in
evaluation of the ECM as it relates to overall muscle health. ECM is known to be dysregulated in
cancer cachexia as fibrosis continues to develop, however fluctuations in Collagen I and
Collagen III in cancer cachexia as it relates to skeletal muscle lack scientific research.
As discussed above, the ECM is crucial for skeletal muscle health maintenance, but
improper regulation of the ECM and its components leads to fibrosis and impaired muscle mass.
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Matrix metalloproteinases (MMPs) are a family of proteases that breakdown collagens and
therefore breakdown the ECM. MMPs are released by a variety of cells such as immune,
myofiber, satellite, epithelial, and fibroblast which themselves are transcriptionally regulated by
inflammatory cytokines such as TGF-β, IL-6, and TNF-α [76, 128]. Although there are many
MMPs, MMP-2 and MMP-9 are consistently found to be linked to ECM degradation and fibrosis
in skeletal muscle across a variety of pathologies [129-132]. Because MMPs are regulated in-part
by inflammatory cytokines known to elevated in cancer cachexia they must play a part in fibrosis
during cancer cachexia, but their exact role has yet to be elucidated.
MMPs regulate collagen and ECM breakdown in response to various stimuli such as
muscle injury and damage. This breakdown of the ECM and its components can be useful such
as when releasing growth factors following muscle damage to aid in the regeneration process,
but chronic elevation of MMPs results in excess fibrosis and only worsens muscle health [121,
133]. Key regulators of MMPs are Tissue Inhibitor of Metalloproteinases (TIMPs) which inhibit
the activity of MMPs [134]. TIMPs aid in maintaining the proper balance of MMP activity for
proper myogenesis and muscle health while limiting fibrotic events to healthy levels [135].
When TIMPs are dysregulated MMPs will be left unchecked ultimately leading to ECM and
skeletal muscle pathology [136, 137]. TIMP-1 and TIMP-2 inhibit MMP-9 and MMP-2,
respectively, and the analysis of MMPs in association with their respective TIMPs is necessary
for measuring degradation and over remodeling of the ECM.
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Sex Differences in Cancer Cachexia

Fig 1-5. Hormonal effects on aspects of skeletal muscle health. RosaCaldwell & Greene, 2019.
Cancer cachexia is a multifaceted wasting syndrome characterized by chronic
inflammation, dysregulated protein turnover, and excessive fibrosis [4, 13, 14, 15, 22, 36]. This
inherent complexity of the condition has made finding effective therapies challenging. Adding to
this challenge is the effect sex has on creating varied responses to treatments and even cancer
cachexia itself [138]. Recent research has been aimed at evaluating cancer cachexia and various
treatments in both sexes [8, 139, 140]. More specifically, research in females has been lacking
where past studies tended to focus exclusively on male subjects to avoid complications that can
arise due to hormonal variations from estrous cycling in females. Interestingly, current literature
suggests that females are more susceptible to wasting from disuse and less susceptible to wasting
from inflammatory conditions such as cancer cachexia [138]. The root causes of these sex
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differences seem to center around muscle protein turnover, satellite cell dynamics, hormones,
and mitochondria (Fig 5).
Hormonal estrogen has been observed as the main driver for female physiology to differ
from males, and past studies of ovariectomized females resulted in increased adiposity,
inflammatory expression, and lethargy [8, 143]. Vice versa, studies adding exogenous estrogen
saw improvements in protection from skeletal muscle wasting [144]. With these improvements
largely attributed to lessened inflammation in females. These recent studies all point to females
displaying greater protection to inflammatory-based pathologies, namely cancer cachexia, due to
the greater protective effects of estrogen on reducing inflammation.
Protein turnover has shown sexual dimorphism mainly in the presence of estrogen, where
reductions in estrogen have been linked to reduced anabolism and increased inflammation and
autophagy [138, 141]. This demonstrates protein turnover as possessing a sensitivity to relative
amounts of circulating estrogen. Like estrogen’s effect on protein turnover, higher testosterone in
males and in subjects with exogenous supplementation of testosterone has been linked to greater
content and proliferation capacity of satellite cells [142]. Recent research also suggests that
males and females may favor or utilize different protein degradation pathways, whether with
proteolysis or autophagy for example [34, 138]. In general, there is no longer a debate on
whether sex can result in variations in muscle pathologies, the focus has now shifted on future
research attempting to better understand the effects of sex on muscle pathologies and therapeutic
interventions.
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Summary
Cancer cachexia is an irreversible wasting condition that affects ~80% of all cancer
patients and is accountable for ~20% of all cancer related mortality [4, 5, 6]. Causes for cancer
cachexia are largely attributed to the chronic inflammation and protein imbalance observed as
cancer progresses [10-13]. These dysregulations result in excessive protein degradation and
fibrosis ultimately leading to skeletal muscle wasting and dysfunction [14-16]. Skeletal muscle
comprises the majority of overall body mass and continuous muscle atrophy in cancer patients
worsens patient outcomes by increasing morbidity and mortality [3].
The role sex plays on cancer cachexia has received little scientific attention until recently
[138]. More recent efforts have been made to evaluate how male and female differences effect
skeletal muscle physiology as it relates to cancer cachexia and even potential therapeutic
interventions [8, 139, 140]. Variations in muscle physiology, hormone balance and protein
turnover are known to occur between both sexes, but the role sex has on leucine supplementation
and fibrosis as they relate to cancer cachexia has not been elucidated.
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Chapter 2
Doctoral Dissertation Proposal
Cancer is the second leading cause of death in the United States according to the Centers
for Disease Control and Prevention (CDC), accounting for ~600,000 deaths yearly and trailing
only heart disease in mortality [1, 2]. Concurrent with many cancers is the development of
continual losses in skeletal muscle associated with cancer progression, otherwise known as
cancer cachexia. This progressive wasting of skeletal muscle tissue is also associated with excess
fibrosis of the extracellular matrix (ECM) and its components within skeletal muscle, and overall
results in worsening of cancer patient health outcomes [3, 4, 5]. In fact, cancer cachexia is
responsible for ~20% of all-cancer related deaths [6, 7, 8]. The difficulty in finding effective
therapeutic approaches to cancer cachexia is due to the multi-factorial nature in which cachexia
can develop, and to date no nutritional interventions have shown to be effective treatments.
Along with current research into cachexia treatments in general is the rising need for evaluation
of how sex has shown to create a divergent response to not only cancer cachexia development
and progression [9], but to potential cachexia interventions as well [10]. Therefore, evaluation of
cancer cachexia between sexes and how both respond to any possible intervention has become of
crucial importance in recent cachexia research.
Cancer cachexia is driven by improper maintenance of protein flux, favoring catabolism
over anabolism [11, 12]. No single nutritional intervention targeting this imbalance has been
effective across all cancer types, but evaluation of cancer cachexia development and progression
between sexes following treatment with a known stimulator of anabolism is lacking. The amino
acid Leucine has been shown to drive anabolism through direct stimulation of mTOR, where an
increase in mTOR activation could theoretically upregulate protein anabolism in order to
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mitigate improper protein turnover [13, 14]. Increased fibrosis is also known to occur in
cachectic patients further worsening losses in skeletal muscle mass [15, 16]. While fibrosis is
known to be upregulated due to cancer progression, the fibrotic response during the early
developmental stages of cachexia is not completely understood. Therefore, the central hypothesis
of this proposal is two-fold: 1) leucine supplementation will induce proteins and related markers
of anabolism, however this could exacerbate cancer cachexia due to the opportunistic nature of
the tumor micro-environment; and 2) increases in fibrosis will be driven by dysregulation of
extracellular matrix maintenance during the early, developmental stages of cancer cachexia. We
also hypothesize there will be a dimorphic response to both leucine supplementation and fibrotic
development between cachectic males and females.
Aim 1. Determine the effect of leucine supplementation on cancer cachexia in males and
females. APCMin/+ male and female mice will be given 1.5% leucine supplemented water (plain
water control) to evaluate the effect of leucine on cancer cachexia. Tissue collection will occur at
20 weeks of age, or when cachexia becomes severe enough that mice become moribund.
Analysis of leucine supplementation and its effect on the cachectic phenotype, inflammatory
markers and protein turnover signaling will be used to elucidate leucine’s specific role on cancer
cachexia.
Aim 2. Analyze fibrosis during the development of cancer cachexia between males and females.
Fibrosis during cancer cachexia development will be analyzed following injection of Lewis-lung
carcinoma cells for 1, 2, 3, and 4wks (0wk PBS control) into the hind flank of male and female
C57BL/6 mice. We will measure markers associated with ECM regulation and fibrosis at all
timepoints to determine the role of the ECM on skeletal muscle mass during the development of
cancer cachexia.
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Aim 3. in vitro analysis of cancer cachexia in muscle cells following treatment with plasma from
leucine supplemented males and females. Blood plasma collected from the APCMin/+ mice in Aim
1 will be administered to differentiated myotube cells to evaluate leucine supplementation in
vitro to go along with the in vivo analyses. Results obtained in Aim 3 will be portrayed alongside
Aim in Chapter 4 in manuscript form.
The experiments outlined above will provide a thorough and novel analysis of the effectiveness
of an anabolism-driven nutraceutical on cancer cachexia, as well as the role fibrosis plays on the
developmental stages of cachexia between both sexes.
Research Strategy
A. Significance
A1. Cancer cachexia lacks an effective treatment and is shown to worsen cancer patient
health and outcomes. Cancer cachexia worsens cancer severity and ultimately cancer patient
outcomes. While skeletal muscle wasting is known to occur in cancer patients, there are no clear
avenues for treatment due to the multi-factorial nature of the disease. This lack of an effective
treatment avenue along with the prevalence and severity of cancer-related deaths has made
cachexia a focal point of recent cancer research and a priority of the National Cancer Institute as
its own grant initiative (PQ6). To date, the efficaciousness of nutraceutical interventions and the
concurrent replacement of skeletal muscle with fibrotic tissue during cancer cachexia lack
thorough evaluation. Due to the lack of effective treatments for cancer cachexia there is still an
urgent need for investigation of novel therapeutics against and processes that contribute to the
development and progression of cancer cachexia.
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A2. Supplementation with leucine may alleviate muscle wasting through activation of
anabolism. Cancer cachexia occurs when rates of protein breakdown are greater than protein
synthesis. This imbalance in protein turnover induces wasting of skeletal muscle and is known to
affect ~50% of all cancer patients. The amino acid leucine has the unique capability to drive
protein synthesis rates to increase via direct stimulation of mTOR. This induction of mTOR and
its downstream effectors (e.g., 4E-BP1) results in translation progression, aiding in protein
synthesis rates. Therefore, the addition of leucine could provide a potent nutraceutical-based
treatment and correct the skeletal muscle wasting observed in cancer cachexia.
A3. Excess fibrosis is associated with cancer cachexia progression but the role of fibrosis in
the developmental stages of early cancer cachexia is not fully understood. The replacement of
healthy muscle mass with non-contractile and fibrotic tissue is a major contributor to cancer
cachexia and its progression. What is less understood is the role of fibrosis towards development
of cachexia in its early stages. The ECM that surrounds skeletal muscle is home to growth
factors (TGF-β) and satellite cells that aid in skeletal muscle mass health and maintenance.
Excessive upregulation of these growth factors ultimately leads to fibrotic infiltration into
healthy skeletal muscle, thereby worsening cancer cachexia. Alterations in the ECM may begin
prior to the development of cancer cachexia, but whether it is true, and the processes involved
lack elucidation.
A4. In vitro analysis of leucine supplementation’s effect on cancer cachexia will allow for a
mechanistic evaluation at the cellular level alongside the in vivo approach used in A1. The
dimorphism in response of males and females to cancer cachexia as well cancer cachexia
treatments produces difficulty in evaluating potential therapies. These known sex differences
require consideration when researching the capability of novel treatments of cancer and cancer
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cachexia. Therefore, we propose to utilize an in vitro analysis of leucine supplementation on
skeletal muscle cells. Addition of blood plasma taken from the non-cachectic and cachectic
animals to skeletal muscle cells in culture will elucidate the role of circulating factors on cancer
cachexia following supplementation with the amino acid leucine. Similarities in protein turnover
and inflammatory signaling between mice in A1 and skeletal muscle cells in A4 will aid in
pinpointing key pathways and processes contributing to cancer cachexia improvements or
worsening severity between sexes. Therefore, results discovered in A4 will be included alongside
those in A1 for a comprehensive analysis of cancer cachexia in conjunction with leucine
supplementation.
My central hypothesis is two-fold: 1) leucine supplementation will induce proteins and
related markers of anabolism, however this could exacerbate cancer cachexia due to the
opportunistic nature of the tumor micro-environment; and 2) increases in fibrosis will be driven
by dysregulation of extracellular matrix maintenance during the early, developmental stages of
cancer cachexia. We also hypothesize there will be a dimorphic response to both leucine
supplementation and fibrotic development between cachectic males and females.
B. Innovation
The proposed studies were innovative due to the targeting of a potent nutraceutical (leucine)
for treatment of cancer cachexia, and the isolation of the early and developmental stages of
cancer cachexia for fibrosis analysis. In vitro duplication of the experiments in Aim 1 also adds
an innovative and robust comparison to strengthen any arguments for or against leucine
supplementation as an appropriate nutraceutical intervention for the treatment of cancer
cachexia. We believe we are the first research group to have such an experiment for in vitro
analysis of leucine supplementation on cancer cachexia by plasma treatment of muscle cells from
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leucine supplemented and cachectic mice. Inclusion of both male and female sexes in all
proposed experiments also adds novelty to past research of leucine supplementation and fibrosis
in cancer cachexia, where past studies are lacking in such considerations of sexual dimorphism.
C. Approach
Overall Approach. In order to test the central hypothesis, we have performed two large
in vivo experiments using male and female mice. APCMin/+ (APC) mice, a well-established model
of cancer cachexia due to colon cancer, were selected for analysis of leucine supplementation as
a potential nutraceutical treatment. This model was chosen as this allows a more prolonged
development of cancer cachexia compared to allograft models to allow an enhanced assessment
of nutraceutical efficacy. LLC mice were created, and tissue harvested at 0, 1, 2, 3, and 4wk
post-injection with 1million Lewis Lung Carcinoma (LLC) cells to isolate the developmental
stages of cancer cachexia for fibrosis analysis. For these studies LLC was chosen as a model to
allow for more careful control of the time course development of cancer cachexia. Plasma was
extracted from the APC mice described above and used to treat muscle cells in culture for a
novel in vitro evaluation of any differences in leucine supplementation on cancer cachexia
prevalence due to sex and their inherent circulating factors.
Specific Aim 1. I hypothesize leucine supplementation will drive increases in markers of
anabolism in both males and females, however this may or may not alleviate cancer cachexia
severity. Preliminary weight data (Figure 1) suggest leucine supplementation worsened losses in
body weight, at least in males, compared to those given normal water. This increased severity in
wasting may be due to the opportunistic nature of cancer, thereby driving cancer growth and
worsening pathways already associated with cancer cachexia progression. To test this hypothesis
and understand why this exacerbated wasting was not observed in females, we evaluated the
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inflammatory, protein turnover, and myogenic profiles of WT and APC mice following leucine
supplementation.
APCMin/+ model of cancer cachexia: APC mice were purchased from Jax Labs. APC-positive
males were bred with C57BL/6 female mice. Mice were genotyped using PCR following
weaning to determine genotype. APC-negative mice were used as a wild-type (WT) control.
Mice were weaned at 4 weeks of age, where they were then supplemented with leucine-enriched
water (1.5%) or normal water as a control. This created 4 experimental groups per sex based on

Figure 2-1. Preliminary body weight data from male and female APC mice supplemented
with normal or leucine-enriched water collected by our lab group.
genotype and leucine supplementation described as WT No Leucine (WT NL), WT Leucine (WT
L), APC No Leucine (APC NL), and APC Leucine (APC L). Tissue was collected at 20 weeks of
age or if mice became moribund prior to harvest date.
Confirmation of cancer cachexia: Muscle wet weights, fat mass and measurements of
muscle cross-sectional area (CSA) will be collected to confirm whether cachexia occurred, as
well as whether there were any variations between groups. CSA measurements will be performed
in conjunction with immunofluorescent fiber typing described below.
Inflammatory Profile: Classification of inflammatory markers associated with cancer
cachexia in APC mice has been well established. Further analysis of known regulators of
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inflammation following leucine supplementation will allow for comparison with past studies on
how leucine exhibits its specific effects on cancer cachexia. This will be accomplished through
measurements of spleen mass, and RT-PCR and Immunoblot inflammatory cytokines such as IL6, TNF-α for a comprehensive analysis.
Protein Turnover: Analysis of markers involved in the synthesis and breakdown of
proteins will confirm the role of leucine on cancer cachexia as it pertains to protein turnover.
This will be completed through RT-PCR and Immunoblot of protein turnover such as p70S6k
and 4E-BP1 similarly to classification of the inflammatory profile described above.
Histological Analysis: Tibialis anterior (TA) muscle was embedded in optimal cutting
temperature (OCT) compound for sectioning of muscle at a thickness of 10µm.
Immunofluorescent labeling of myosin heavy chains (MHCs) I, IIa, IIb in TA cross-sections will
be performed for measurements of any shifts in fiber type composition. Labeling of these fibers
will also allow for tracing of individual muscle fibers for CSA measurements for confirmation of
muscle wasting due to cancer cachexia.
Statistical Analyses: Differences between groups will be determined via Two-way
ANOVA for a global analysis, where a Tukey’s post hoc test will then be performed to evaluate
differences between means. All Two-way ANOVAs will be performed within sex and are not
meant for direct comparisons between male and female data. Data was determined parametric via
a Shapiro-Wilk test. Statistical significance will be set at α=0.05 and β=0.20 (power = 0.80).
Anticipated Results and Interpretation of Findings: We expect leucine supplementation
to alter markers of protein anabolism in WT and APC mice. Our preliminary data (Figure 1)
show that leucine supplementation had a negative impact on skeletal muscle wasting at least in
male mice. Analysis of the inflammatory profile and markers associated with protein turnover
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will help to elucidate the major contributors towards the worsening of cancer cachexia induced
by leucine supplementation.
Specific Aim 2. We hypothesized dysregulation of the ECM will coincide with cancer
cachexia development in males and females, but there would be variations in severity and the
signaling pathways contributing to the fibrotic response. To test this hypothesis, male and female
mice were injected with either phosphate buffered saline (PBS) or LLC cells for 0 (PBS only), 1,
2, 3, and 4wks. Published data from our research group has demonstrated that cachexia
developed at 4wks in these mice, therefore alterations in ECM signaling and composition in the
weeks prior could identify key regulators of fibrosis during cancer cachexia development.

Table 2-1. Weight data from male LLC model of cancer cachexia. Brown et al.,
2017.
Culturing of LLC Cells: LLC cells were cultured in 10% Fetal Bovine Serum Growth
Media with 1% Penicillin and Streptomycin added. Once confluent, cells will be trypsinized,
counted and diluted in PBS for implantation.
Induction of muscle atrophy by cancer-cachexia: LLC cells will be implanted into the
hind flank of anesthetized C57BL/6 mice at a concentration of 1X106 cells in a 100 µL
suspension of sterile PBS. The LLC tumor will be allowed to develop for up to 4 wks with
cohorts harvested weekly. Sterile PBS was injected for a 0wk control group.
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Confirmation of model: Tissue wet weights were measured for confirmation of muscle
wasting due to cancer cachexia. Fibrosis and Collagen
Analysis: Fibrosis will be quantified by histological
staining of TA cross-sections via Picro Sirius Red.
Picro Sirius Red stains collagen, the major component
of the extracellular matrix, allowing for quantification
of collagen deposition and overall fibrosis in skeletal
muscle as cancer cachexia develops. We will also
perform immunofluorescent labeling of Collagens 1
and 3 in TA cross-sections, where we can then create
an analysis of the relative amount of Collagen 1 to

Figure 2-2. Preliminary data of
collagen staining of skeletal muscle
cross-sections via Picro Sirius Red.

Collagen 3. Collagen 1 is a more rigid collagen fiber,
whereas collagen 3 has greater elasticity and is more tensile. Changes in the relative amounts of
these collagen fibers can indicate alterations in the ECM surrounding skeletal muscle as it
pertains to fibrosis due to cancer cachexia.
ECM dynamics: RT-PCR and Immunoblot of collagens and regulating factors of the
ECM within skeletal muscle will aid in identification of key molecules and processes that
contribute to fibrosis during the development of cancer cachexia. RT-PCR and Immunoblot
targets are as follows: Collagen 1, Collagen 3, MMP-2, MMP-9, Timp-1, TGF-β, β-catenin,
SMAD 2, and SMAD 3.
Muscle cell and Fibroblast cell Co-culture: C2C12 myoblast cells and 3T3 fibroblast
cells will be co-cultured in vitro for analysis of the same ECM-related pathways and markers
described in the in vivo approach. C2C12 cells will be grown until they reach ~80% confluency,
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where they will then be transferred to a 6-well plate and differentiated for 5 days. 3T3 fibroblast
cells will then be added via a transwell-insert, which possesses a semi-permeable membrane, into
the 6-well plate for creation of a skeletal muscle to ECM connection in vitro. LLC conditioned
media (LCM) or control media will then be added to both cell types for 24hr, where we will then
harvest both for the same RT-PCR and Immunoblot analyses described in the in vivo approach.
Confirmation of cancer cachexia will be confirmed via measurements of myotube diameter prior
to cell harvest.
LLC conditioned media: LLC cells were grown to 100% confluence. Media was then
filtered and diluted to 25% total volume in serum free media. For the Control group, 10% fetal
bovine serum growth media was diluted to 25% total volume with serum free media.
Statistical Analyses: Differences between groups will be determined via One-way
ANOVA for a global analysis, where a Student’s Newman Keuls post hoc test will then be
performed to evaluate differences between means. Data was determined parametric via a
Shapiro-Wilk test. Statistical significance will be set at α=0.05 and β=0.20 (power = 0.80).
Anticipated Results and Interpretation of Findings: We expect ECM dynamics to be
altered and fibrosis to increase as cancer cachexia begins to develop. This will be reflected in
modifications to pathways and markers associated with ECM remodeling, and further reflected
in changes to the ratio of Collagen 1 to Collagen 3 at the tissue level. However, these alterations
will likely vary between males and females.
Specific Aim 3. We hypothesize addition of blood plasma from leucine supplemented
and control mice to muscle cells in culture would aid in identification of the major pathways
contributing to cancer cachexia between sexes. in vitro addition of plasma from male and female
APC mice will aid in isolation of the dimorphic pathways responsible for the state of cancer
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cachexia. This experiment gives a mechanistic boost in approach for analysis of leucine’s
capability, or potentially lack thereof, to alleviate cancer cachexia in both sexes.
Plasma Treatments: Plasma extracted from the female and male WT and APC mice used
in Aim 1 will be added to cultured myotubes for in vitro analysis of cancer cachexia following
leucine supplementation.
Cachectic Plasma Analyses: We will measure myotube diameter along with all RT-PCR
and Immunoblot targets outlined in the in vivo approach in Aim 1. These analyses will ultimately
provide a comprehensive comparison of leucine supplementation at the in vivo and in vitro level
for both sexes. Any similarities or differences observed in RT-qPCR and Immunoblot targets at
the in vivo or in vitro level will aid in elucidation of the major contributors of leucine’s effect on
cancer cachexia.
Statistical Analyses: Differences between groups will be determined via Two-way
ANOVA for a global analysis, where a Tukey’s post hoc test will then be performed to evaluate
differences between means. All Two-way ANOVAs will be performed within sex and are not
meant for direct comparisons between male and female data. Data was determined parametric via
a Shapiro-Wilk test. Statistical significance will be set at α=0.05 and β=0.20 (power = 0.80).
Anticipated Results and Interpretation of Findings: We expect the in vitro results to
mirror those which are observed in vivo in Aim 1 on a sex-to-sex basis. Any variations will likely
be minor, as plasma contains any circulating factors relative to each sex obtained from the WT
and APC mice.
Summary. Cancer is a leading cause of death across the globe. Cancer cachexia is
cancer-associated wasting of skeletal muscle that affects ~50% of all cancer patients, worsening
patient outcomes. Due to the prevalence and severity of cancer and cancer cachexia there are
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countless completed and ongoing studies aiming to better understand this multi-factorial wasting
condition and how to properly treat it. Current nutritional interventions are ineffective at treating
cancer cachexia, but not all nutraceutical avenues have been pursued. Fibrosis is known to
coincide with cancer cachexia and its progression, but literature is lacking on how fibrosis and
ECM dysregulation contribute to the initial development of cancer cachexia. Therefore, this
proposal aims to evaluate a potent stimulator of anabolism, in the amino acid leucine, and
fibrotic pathways in cancer cachexia and cancer cachexia development.
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Abstract
Cancer cachexia is a multi-factorial wasting syndrome that affects up to 80% of all cancer
patients and is responsible for 20-40% of all cancer related deaths. To date, nutritional
interventions have shown to be ineffective in alleviating cancer cachexia but there remains a lack
of understanding as to why. More importantly, research is severely lacking in evaluation of
nutraceutical interventions for cancer cachexia across both sexes. The purpose of this study was
to evaluate the effects of leucine supplementation on cancer cachexia in both male (n=28) and
female (n=32) APCMin/+ (APC) and wild-type (WT) mice. Mice were supplemented with regular
or leucine-enriched water following weaning up until euthanasia at 20 weeks of age. Male APC
L mice exhibited exacerbated wasting with decreased body weight compared to male APC NL
mice, and this effect of leucine was not observed in female APC mice. IL-6 mRNA was elevated
in male APC L mice compared to male APC NL mice and this effect was also not observed in
female mice. Female APC mice displayed greater MyoD mRNA abundance compared to WT
and this was not observed in male mice. Myotube diameter was reduced following addition of
blood plasma derived from male APC NL & L mice compared to WT but myotube diameter was
unchanged following addition of female APC plasma. Our results indicate sexual dimorphism in
markers of inflammation, protein anabolism and catabolism, and myogenesis during cancer
cachexia following supplementation with leucine. We provide novel evidence for leucine
supplementation to affect male and females differently during cancer cachexia and further
highlights the need for inclusion of both sexes in future research.
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Introduction
Cancer is a leading cause of death worldwide according to the World Health
Organization (WHO), with estimations of upwards to ~10 million deaths in 2019. In the U.S.
alone, it is estimated ~600,000 people perished as a result of cancer in the year 2020 by the
American Cancer Society (ACS), and according to the Center for Disease Control (CDC) ~39%
of all men and women acquire some form of cancer in their lifetime. Cancer cachexia is a
multifactorial wasting syndrome defined by losses of lean mass >5%, that can be accompanied
with or without losses in fat mass and will affect ~80% of all cancer patients to varying extent (1,
2). Also of note, up to 40% of all cancer deaths can be directly attributed to cancer cachexia as it
worsens patient health and overall outcomes (3). Currently no therapeutic interventions have
shown to be effective in the treatment of cancer cachexia due to the pathology’s multifactorial
induction and regulation through a negative energy balance, systemic inflammation, and
hormonal imbalances (4-6). Current scientific research has been aimed at understanding these
cachexia-induced dysregulations in order to elucidate potential avenues for intervention but to
date there is no current consensus of treatments with consistent efficacy (7).
Cancer cachexia is a wasting syndrome partially characterized by the favoring of
catabolism over anabolism of proteins, as a result there has been numerous studies evaluating
nutritional interventions on correcting this imbalance (8-10). To date these nutritional
interventions have largely been proven ineffective across multiple models of cancer cachexia,
however there is still a considerable lack of understanding as to the mechanisms that contribute
to the inefficiency of nutritional interventions. L-leucine is a branched chain amino acid known
to stimulate activation of mammalian target of rapamycin (mTOR) in the protein synthesis
pathway. Studies utilizing leucine as a potential therapeutic have observed improvements in
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mitochondrial quantity (11), reductions in protein inhibition and improved protein synthesis (12),
improvements in inflammatory markers IL-6 and TNF-α (13), as well as increasing mTOR
activation in various models of cancer cachexia (14). Therefore, utilization of a potent
nutraceutical such as leucine could provide therapeutic benefits to cachectic cancer patients.
Adding into the overall difficulty and complexity of evaluating cancer cachexia is the
emerging role that males and females display a sexual dimorphism to cancer, cancer cachexia,
and even cancer treatments (15-20). For example, females in general tend to benefit from the
anti-inflammatory effects of estrogen and therefore can experience lesser losses in body weight,
muscle mass, and muscle function compared to males during cancer cachexia (17). Skeletal
muscle of females also exhibits greater mitochondrial quality and fatigue resistance (17, 21).
Recent studies overall indicate greater susceptibility of male skeletal muscle to cancer cachexia
(17, 22), but very few studies have directly compared this sexual dimorphism simultaneously and
most that do exist focused on phenotypic observations (23, 24). Further evaluation of cancer
cachexia and potential therapeutics is critical to a holistic understanding of this pathology as
cancer and cancer cachexia affects both sexes indiscriminately.
To our knowledge, there has not been a study on leucine supplementation as a nutritional
intervention across both sexes in a common model of cancer cachexia. Therefore, the purpose of
this study was to utilize the well-known model of cancer cachexia in the APCMin/+ strain of male
and female mice in conjunction with leucine supplementation. By supplementing their normal
diet with leucine, we hypothesized that male and female mice would exhibit reductions in muscle
wasting as cancer cachexia progressed. We tested this hypothesis by taking phenotypic
measurements as well as a comprehensive analysis of key signaling pathways surrounding
protein turnover and inflammation that are known to be particularly dysregulated in APCMin/+
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(APC) mice. As shown in the results of this study, leucine supplementation exacerbated cancer
cachexia in male but not female mice. However, the direct link to this difference remains unclear
and requires further evaluation in future research.
Methods
Animals and Interventions
All animal experiments were approved by the Institutional Animal Care and Use
Committee (IACUC) of the University of Arkansas, Fayetteville. APC-positive male mice and
APC-negative female mice were initially purchased from Jackson Laboratories for APC colony
production. APC-positive males were bred with C57BL/6 female mice as colon cancer is a
contraindication for pregnancy. Mice were genotyped using semi-quantitative PCR following
weaning to determine genotype. Males and females determined to be APC-negative following
genotyping were used as a wild-type (WT) control. Mice were weaned at 4 weeks of age, where
they were then supplemented with leucine-enriched water (1.5%) or normal water as a control
until tissue collection and euthanasia at 20 weeks of age. This created 4 experimental groups per
sex based on genotype and leucine supplementation described as: WT No Leucine (WT NL;
Male n=7, Female n=8), WT Leucine (WT L; Male n=7, Female n=8), APC No Leucine (APC
NL; Male n=7; Female n=8), and APC Leucine (APC L; Male n=7; Female n=8). Tissue was
collected at 20 weeks of age or if mice became moribund prior to harvest date. Animal tissues,
organs, and blood plasma were collected under isoflurane anesthesia prior to euthanasia. Tissues
were weighed and snap-frozen in liquid nitrogen for further processing and stored at −80°C. The
tibialis anterior (TA) muscle was submerged in optimum cutting temperature compound (OCT)
and then placed in liquid nitrogen cooled isopentane. OCT mounted tissue was then stored at 80°C for future histological and microscopic analysis.
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RNA Isolation, cDNA synthesis, and Quantitative Real-Time PCR
RNA isolation, cDNA synthesis, and quantitative real-time PCR were performed as we
have previously described (25, 26). All targets were assayed using Taqman probes for the
following targets: 18S (Mm03928990_g1), IL-6 (Mm00446190_m1), IL-1β
(Mm00434228_m1), MyoD (Mm00440387_m1), MyoG (Mm00446194_m1), Pax7
(Mm01354484_m1), NFκB (Mm00476361_m1), TNF-α (Mm00476361_m1), UBC
(Mm01198158_m1), Deptor (Mm01195339_m1), IGF-1 (Mm00439560_m1), Foxo1
(Mm00490671_m1), Foxo3 (Mm01185722_m1), Atrogin-1 (Mm00499523_m1), MuRF-1
(Mm01185221_m1). Taqman probes were purchased from Applied Biosystems. RT-qPCR
measured cycle threshold (Ct) and the ΔCt value was calculated as the difference between the Ct
value and the 18S Ct value. Final quantification of mRNA abundance was calculated using the
ΔΔCT method Ct = [ΔCt(calibrator) – ΔCt(sample)]. Relative quantifications were then
calculated as 2-ΔΔCt. 18S Ct values were confirmed to not differ between experimental
conditions for any comparison.
Immunoblotting
Immunoblotting was performed as we have previously described (25, 26). Protein
concentration and equal loading of SDS-page gels was determined via RC DC assayTM (BioRad), and target protein content was normalized to Ponceau S staining of 45kDa band.
Membranes were probed overnight for primary antibodies. Protein targets were purchased from
Cell Signaling Technology (CST) and selected based upon prior literature targeting key
components of inflammation and protein turnover (27-28). Antibodies were diluted in Trisbuffered saline, 0.1% Tween 20 with 5% milk. Membranes were imaged on LiCor Odyssey FC
using IR detection and images analyzed by LiCor Image StudioTM.
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Histology
TA muscle stored in OCT were cryosectioned into 10μm thick sections on polarized
microscope slides. Muscle sections were then histologically stained with Succinate
Dehydrogenase (SDH) for quantification and analysis of oxidative muscle phenotype by
counting relative presence of SDH+ (purple) and SDH- (white) fibers within the TA muscle.
Following SDH staining, cross-sectional area (CSA) of muscle was determined by manually
tracing of SDH+ and SDH- fibers by a blinded researcher. Images were analyzed using Nikon
NIS Elements BR software package.
in vitro APCMin/+ Plasma Treatment
C2C12 myoblast cells (ATCC CRL-1772) were cultured for an in vitro analysis of the
effect of blood plasma derived from all male and female groups on myotubes. C2C12 cells were
grown until they reached ~80% confluency at passage 2, where they were then transferred to a 6well plate and differentiated for 5 days. Plasma-infused media was created by taking blood
plasma from a single representative mouse from all treatment groups and adding to serum free
DMEM at a concentration of 20μL/mL of media. Cells were treated with the plasma-infused
media for over 24hr after differentiation, where they were then harvested for subsequent RTqPCR and Western Blot analysis.
Statistical Analysis
All data was determined parametric via a Shapiro-Wilk test prior to any
parametric analysis. Differences between groups was determined via Two-way ANOVA for a
global analysis, where a Tukey’s post hoc test was then performed to evaluate differences
between means following a significant F-test. All Two-way ANOVAs were performed within
sex and are not meant for direct comparisons between male and female data. Statistical
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significance was set at α=0.05. All data were analyzed using the Statistical Analysis System
(SAS) and figures were compiled using GraphPad Prism and data expressed as mean ± standard
error of the mean (SEM).
Results
Confirmation of Cancer Cachexia and Effect of Leucine Supplementation
Cancer cachexia was confirmed in males and females via body, tissue, and organ weights
in Figure 1. Male APC NL mice had decreased body weight ~17% compared to WT mice and
APC L mice exhibited further losses in body weight of ~12% compared to APC NL mice
(p<0.05; Figure 1A). There was a main effect of the APC genotype to reduce tibialis anterior (M
= ~34%; F = ~13%), gastrocnemius (M = ~40%; F = ~32%), plantaris (M = ~16%; F = ~27%),
and soleus weight (M = ~12%; F = ~12%) (p<0.05; Figure 1B-E). There was a main effect of the
APC genotype to increase spleen weight ~550% in male mice and ~400% in female mice
(p<0.05; Figure 1F). There was a main effect of genotype to reduce fat weight ~91% in male
mice and ~98% in females, although there was no detectable fat in the APC L females (p<0.05;
Figure 1G). Male APC L appeared to develop severe cachexia to the extent where all male APC
L mice became moribund and did not survive to the 20-week end point of this study (Figure 2A).
This effect was not observed in female APC L mice and male APC L mice exhibited significant
losses in body weight of ~11% by 14 weeks of age, also not observed in female mice, and this
significant loss in body weight was never recovered prior to euthanasia (p<0.05; Figure 2A &
2B). Survival curves in Figure 2C and 2D show drops in survival rate by 10% by 14 weeks, 40%
by 19 weeks, and 100% by 20 weeks in male APC L mice, whereas female APC NL were the
only group to lose subjects prior to the 20-week euthanasia. We also note that water and food
intake did not differ across either sex or treatment group.
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Sexual Dimorphism of Inflammation
mRNA abundance of the classical markers of cancer cachexia associated inflammation
were analyzed in vivo and in vitro. IL-6 mRNA abundance was ~3.5-fold greater in both APC
groups compared to WT in male mice, and IL-6 mRNA was ~2-fold greater in APC L compared
to APC NL (p<0.05; Figure 3A). In female mice there was a main effect of APC to have ~4-fold
greater IL-6 mRNA compared to WT mice (p<0.05; Figure 3E). There were no differences in
TNF-α and NFκB mRNA in male mice (p>0.05; Figure 3B & 3C), but there was a main effect of
APC to have ~1.5-fold and ~0.5-fold greater mRNA abundance of TNF-α and NFκB in female
mice compared to WT, respectively (p<0.05; Figure 3F & 3G). IL-1β mRNA was elevated ~3fold and ~7-fold in both male and female APC mice compared to WT (p<0.05; Figure 3D & 3H).
There was a main effect of the APC genotype to increase IL-6 mRNA abundance ~1 and ~3-fold
in male and female plasma-treated myotubes compared to WT (p<0.05: Figure 3I & 3M). TFN-α
mRNA was increased ~1-fold in WT L compared to WT NL treated myotubes from male
plasma, but there was a ~1-fold reduction in TNF-α mRNA in APC L compared to APC NL
treated myotubes (p<0.05; Figure 3J). In female plasma treated myotubes there was a main effect
of APC genotype to increase TNF-α mRNA abundance ~1-fold (p<0.05; Figure 3N). There were
no differences in NFκB mRNA in male plasma treated myotubes (p>0.05; Figure 3K), however
NFκB mRNA was elevated ~1-fold in APC plasma treated myotubes (p<0.05; Figure 3O). There
was a main effect of APC to increase IL-1β mRNA ~1 and ~0.5-fold in male and female plasma
treated myotubes, respectively (p<0.05; Figure 3L & 3P).
Markers of Atrophy, Proteolysis and Protein Anabolism Inhibition
There was a main effect of APC mice to have increased FOXO1 and FOXO3 mRNA
abundance in male and female mice ~2-fold and ~3-fold, respectively (p<0.05; Figure 4A, B, E
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& F). There were no differences in Deptor mRNA in either male or female mice (p>0.05; Figure
4C, D, G & H), but there was a main effect of APC mice to have ~2-fold higher UBC mRNA
abundance compared to WT (p<0.05; Figure 4D & H). FOXO1 mRNA was ~1-fold greater in
APC female plasma treated myotubes compared to WT (p<0.05; Figure 4M) and was not
different in male plasma treated myotubes (p>0.05; Figure 4I). There were main effects of
FOXO3 to be altered in male and female APC plasma treated myotubes, but alterations differed
in male APC myotubes to have ~0.5-fold less FOXO3 mRNA (p<0.05; Figure 4J) and female
APC myotubes to have ~2-fold greater mRNA abundance when both were compared to WT
(p<0.05; Figure 4N). No alterations were detected in Deptor mRNA either male or female
plasma treated myotubes (p>0.05; Figure 4K & 4O). UBC mRNA was reduced ~0.3-fold in male
APC plasma treated myotubes (p<0.05; Figure 4L) but no differences in female plasma treated
myotubes were detected (p<0.05; Figure 4P).
Muscle Myogenesis
No differences in Pax7 mRNA abundance were detected in either male or female mice
(p>0.05; Figure 5A & E). MyoD was increased ~2-fold in female APC mice compared to WT
(p<0.05; Figure 5F), but no differences were observed in male mice (p>0.05; Figure 5B). There
was a main effect for Myogenin mRNA to be increased in male and female APC mice ~1 and
~2-fold, respectively (p<0.05; Figure 5C &G). IGF-1 mRNA did not change across WT and
APC groups in either sex (p>0.05; Figure 5D & 5H).
There were main effects for genotype to decrease Pax7 mRNA and for leucine to increase
Pax7 in male plasma treated myotubes (p<0.05; Figure 5I). Pax7 mRNA was elevated ~0.5-fold
in WT L compared to WT NL plasma treated myotubes, but APC L myotubes exhibited ~0.5fold less mRNA compared to APC NL myotubes (p<0.05; Figure 5M). MyoD mRNA abundance
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did not differ in any groups for male and female plasma treated myotubes (p>0.05; Figure 5J &
5N). There was a main effect for leucine to increase IGF-1 mRNA abundance ~0.3-fold in male
plasma treated myotubes (p<0.05; Figure 5L). IGF-1 mRNA was increased in WT L treated
myotubes ~0.3-fold, but APC L treated myotubes saw a ~0.3-fold decrease in IGF-1 mRNA
abundance (p<0.05; Figure 5P).
Protein Anabolism
Male mice had no changes in phospho:total AKT protein content (p>0.05; Figure 6A), but
female mice saw ~0.5-fold more phospho:total AKT in WT L compared to WT NL and ~0.3-fold
less phospho:total AKT in APC L compared to APC NL mice (p<0.05; Figure 6D). There was a
main effect of leucine supplementation to increase phoshpo:total p70 protein content in both
male and female WT and APC mice ~2-fold (p<0.05; Figure 6B & 6E). There was a main effect
of the APC genotype and leucine supplementation to increase phospho:total 4E-BP1 protein
content in male mice ~2-fold (p<0.05; Figure 6C) and a main effect of leucine to increase
phospho:total 4E-BP1 protein content ~2-fold in female mice (p<0.05; Figure 6F). There was a
main effect of blood plasma from leucine supplemented male mice to have ~0.5-fold
phospho:total AKT protein in myotubes (p<0.05; Figure 6G), however plasma from leucine
supplemented female mice resulted in a ~0.5-fold increase in phospho:total AKT protein
(p<0.05; Figure 6J). No differences in phospho:total p70 and 4E-BP1 protein were detected in
male plasma (p>0.05; Figure 6H & I). Phospho:total p70 protein was ~0.3-fold lower in WT L
plasma treated myotubes compared to WT NL, but APC L plasma treated myotubes saw ~0.4fold increase phospho:total p70 protein compared to APC N (p<0.05; Figure 6K). There was a
main effect for female APC plasma to increase phospho:total 4E-BP1 content compared to WT
(p<0.05; Figure 6L).
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Deeper Dive into Protein Breakdown
There was a main effect for APC mice to have ~7-fold greater Atrogin-1 mRNA
abundance in male mice and ~3-fold greater Atrogin-1 mRNA in female mice compared to WT
(p<0.05; Figure 7A & D). MuRF-1 mRNA was elevated ~5-fold in male and female APC mice
compared to WT (p<0.05; Figure 7B & E). There were no changes in ubiquitin protein content in
either male or female mice (p>0.05; Figure 7C & F). Atrogin-1 mRNA abundance was decreased
~0.4-fold in APC compared to WT mice in male plasma treated myotubes (p<0.05; Figure 7G).
There was a main effect of the APC genotype and Leucine supplementation to increase Atrogin1 mRNA in ~2-fold in APC plasma treated myotubes compared to WT treated (p<0.05; Figure
7J). MuRF-1 mRNA was increased ~0.3-fold in WT and APC male plasma treated myotubes due
a main effect of leucine, and APC had a main effect of decreasing MuRF-1 mRNA ~0.3-fold
compared to WT (p<0.05; Figure 7H). There was a main effect of APC to elevate MuRF-1
mRNA abundance ~2.2-fold in female plasma treated myotubes (p<0.05; Figure 7K). Ubiquitin
protein content was decreased ~0.7 and ~0.5-fold in WT NL male plasma treated myotubes
compared to WT L and both APC groups (p<0.05; Figure 7I). No differences in ubiquitin protein
content were detected between any groups in female plasma treated myotubes (p>0.05; Figure
7L).
Skeletal Muscle CSA and Myotube Diameter
There was a main effect of the APC genotype to reduce CSA of skeletal muscle in both
male and female mice ~27% and ~30%, respectively (p<0.05; Figure 8A-D). These decrease in
muscle CSA were the same regardless of leucine supplementation or being identified as SHD (+)
or SDH (-) fibers (p>0.05; Figure 8A-D). Myotube diameter was decreased following addition of
male APC plasma ~13% when compared to WT plasma treated myotubes (p<0.05; Figure 8E).
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No changes in myotube diameter following addition of female plasma were detected across any
groups (p>0.05; Figure 8F).
Discussion
Cancer cachexia is a thoroughly researched model of muscle wasting that is notably
characterized by chronically elevated and systemic inflammation (29-31). Nutritional
interventions have also been thoroughly researched in treating cancer cachexia with little to no
success (8-10). Yet there remains little research of nutritional interventions on cancer cachexia
across both sexes, and therefore, in this study we aimed to investigate the effects of leucine
supplementation on cancer cachexia and how sex can influence the outcome. The simplest and
yet major finding observed in this study was the effect of leucine supplementation to reduce
body weight in male APC mice ~12% compared to APC NL mice. This effect of leucine
supplementation to decrease overall body weight was not observed in female mice, even though
both sexes displayed similar decreases in muscle, tissue and organ weights due to cancer
cachexia. In both male and female APC mice, skeletal muscle CSA was reduced regardless of
oxidative phenotype (+ or -) and leucine supplementation had no added effect. Of note, myotube
diameter decreased significantly following addition of either male APC NL or APC L blood
plasma whereas female plasma created no differences in myotube diameter across group. To our
knowledge, this study is the first to report this effect of leucine to potentially exacerbate cancer
cachexia but in a sex-dependent fashion in vivo.
Elevated levels of IL-6 are well documented in APC mice (32-35) and our findings
further support this observation, especially in male APC mice where their decreased body weight
following leucine supplementation corresponded with an increase IL-6 mRNA abundance. While
female mice displayed no increases in IL-6 mRNA following leucine supplementation, female
APC mice did have higher TNF-α and NFκB mRNA abundance compared to WT which was not
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observed in males. These variations in inflammatory markers suggests potential differences in
downstream effectors and pathways influencing cachectic wasting between sexes. It is
noteworthy to mention that the rise in TNF-α and NFκB mRNA translated to female plasma
treated myotubes as well, although male plasma treated myotubes interestingly saw increases and
decreases in TNFα due to leucine in WT and APC plasma, respectively. TNF-α and NFκB have
previously been linked to the E3 ligases Atrogin-1 and MuRF-1 in models of colorectal cancer
(36-38) and following these observations we evaluated the E3 ligases and total ubiquitin protein
content. However, we saw no clear trends pinpointing the observed differences in IL-6, TNF-α,
and NFκB to impact rates of proteolysis and support the dimorphic impact of leucine on body
weight between sexes. This contrasts previous findings by Baltgavis et al. and White et al. in
2009 and 2011 (39, 40), where elevations in IL-6 were tied to increased Atrogin-1 and
ubiquitination of proteins in APC mice. So, while leucine supplementation appeared to impact
cancer cachexia negatively and selectively in males, the exact cellular process responsible
beyond elevated IL-6 remains unclear.
FOXO1 and FOXO3 are the key effectors involved in ubiquitination of proteins targeted
for degradation by the ubiquitin proteasome system (UPS) downstream of E3 ligase induction,
both of which have been shown to be upregulated in cancer cachexia (41, 42). Here we report
APC mice having increased FOXO1, FOXO3, and UBC mRNA regardless of sex and all of
these increases translated in vitro except for FOXO1 in male plasma and UBC in female plasma.
While not completely consistent in vivo and in vitro these findings support increased rates of
proteolysis during cancer cachexia in both sexes, with leucine having no added effect. In female
APC mice there was an interesting finding for ~2-fold increased MyoD mRNA abundance not
observed in males. While both sexes had increases in Myogenin mRNA in APC mice, the
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elevation of both MyoD and Myogenin could indicate enhanced satellite cell activation and
differentiation to upregulate myogenesis and combat cachexia associated muscle wasting. That
MyoD was not elevated in male APC mice similar to females could be of importance as well in
this regard. Elevation of Myogenin translated to female APC plasma treated myotubes, and
interestingly Pax7 mRNA was decreased in female APC L treated myotubes compared to APC
NL. Taking that data in conjunction with male APC L treated myotubes having a ~0.3-fold
reduction in Myogenin compared to APC NL supports the possibility for female-specific muscle
protection in cancer cachexia via a shift in myogenesis to strongly favor activation and
differentiation of satellite cells. A recent study by Lim et al., 2021 (43) also reported reductions
in Pax7 and MyoD in a Lewis Lung Carcinoma (LLC) model of cancer cachexia. The
conservation of this observation in myogenic regulatory factors suggests a potentially large role
for myogenesis in protection of skeletal muscle in females affected by cancer cachexia.
Leucine supplementation increased protein content of mTOR’s downstream effectors
p70s6K and 4E-BP1 in mice, regardless of genotype or sex. We observed no changes in p70s6k
or 4E-BP1 protein in male plasma treated myotubes and increases in 4E-BP1 in both female
APC plasma treated myotube groups. Overall, the anticipated effects of leucine supplementation
on markers of protein anabolism translated to both sexes in vivo but not in vitro. IGF-1 mRNA
was unchanged in vivo but leucine supplementation increased IGF-1 in male WT and APC
plasma treated myotubes, whereas female APC L plasma treated myotubes saw decreased IGF-1
mRNA. The lack of consistency in vivo to in vitro points to the added complexity of comparing
males and females, as we note vast differences in protein anabolism likely contributable to sex
specific circulating factors in these mice.
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In conclusion, we aimed to investigate the effects of leucine supplementation on cancer
cachexia in both sexes. The divergence in markers of inflammation, protein anabolism, and
myogenesis between males and females during cachexia reported here highlights the need for
inclusion of both sexes in future studies, as interventions in pathologies can have sex-based
effects on patient outcomes. This need for inclusion of both sexes is even enhanced when
considering leucine had such a potent effect to exacerbate cancer cachexia in males, as noted by
increased losses in body weight and increased mortality. While leucine supplementation
exacerbated cancer cachexia in males, the exact mechanisms involved downstream of IL-6, TNFα and NFκB remain unclear. Further research is required but potential therapies that target these
inflammatory pathways may prove beneficial to those suffering from cancer cachexia more so
than those targeting protein anabolism.
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Figure Legends
Figure 1. Descriptive Measurements
Body (A), muscle (B-E), and tissue weights (F-G) of male and female WT and APC mice. All
values are represented as means ± SEM. Main effects of genotype and leucine are labeled as
such, and different letters signify differences in means between groups following an interaction
with significance set at p<0.05.
Figure 2. Body Weights and Survival Rate
Body weight (A-B) and percent survival (C-D) of male and female WT and APC mice. Body
weights are represented as means ± SEM and percent survival as relative percentage. Single
asterisks signify significance from WT only and double asterisks signify significance compared
to APC NL with p<0.05.
Figure 3. Inflammation
mRNA analysis of inflammatory markers in male and female mice as well as plasma treated
myotubes (A-P). Values are represented as means ± SEM. Main effects of genotype and leucine
are labeled as such, and asterisks denote differences between means following an interaction
with alpha set at p<0.05.
Figure 4. Protein Degradation
mRNA analysis of protein breakdown in male and female mice as well as plasma treated
myotubes (A-P). Values are represented as means ± SEM. Main effects of genotype and leucine
are labeled as such, and asterisks denote differences between means following an interaction
with alpha set at p<0.05.
Figure 5. Myogenesis
mRNA analysis of markers of myogenesis in male and female mice as well as plasma treated
myotubes (A-P). Values are represented as means ± SEM. Main effects of genotype and leucine
are labeled as such, and asterisks denote differences between means following an interaction
with alpha set at p<0.05.
Figure 6. Protein Anabolism
Protein content of markers associated with protein anabolism in male and female mice as well as
plasma treated myotubes (A-P). Values are represented as means ± SEM. Main effects of
genotype and leucine are labeled as such, and asterisks denote differences between means
following an interaction with alpha set at p<0.05.
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Figure 7. Deeper Dive into Protein Degradation
mRNA abundance of markers of protein breakdown in male (A-B) and female mice (D-E) as
well as male (G-H) and female (J-K) plasma treated myotubes. Protein content of ubiquitin in
male and female mice (C & F) and male and female plasma treated myotubes (I & L). Values are
represented as means ± SEM. Main effects of genotype and leucine are labeled as such, and
asterisks denote differences between means following an interaction with alpha set at p<0.05.
Figure 8. Microscopy in vivo and in vitro
Cross-sectional area of TA muscle in male and female mice (A-D). Myotube diameter following
addition of blood plasma from male and female mice (E-F). Values are represented as means ±
SEM. Main effects of genotype and leucine are labeled as such, and asterisks denote differences
between means following an interaction with alpha set at p<0.05.
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Figures

Figure 1. Body (A), muscle (B-E), and tissue weights (F-G) of male and female WT and
APC mice. All values are represented as means ± SEM. Main effects of genotype and leucine
are labeled as such, and different letters signify differences in means between groups
following an interaction with significance set at p<0.05.
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Figure 2. Body weight (A-B) and percent survival (C-D) of male and female WT and APC
mice. Body weights are represented as means ± SEM and percent survival as relative
percentage. Single asterisks signify significance from WT only and double asterisks signify
significance compared to APC NL with p<0.05.
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Figure 3. mRNA analysis of inflammatory markers in male and female mice as well as
plasma treated myotubes (A-P). Values are represented as means ± SEM. Main effects of
genotype and leucine are labeled as such, and asterisks denote differences between means
following an interaction with alpha set at p<0.05.
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Figure 4. mRNA analysis of protein breakdown in male and female mice as well as plasma
treated myotubes (A-P). Values are represented as means ± SEM. Main effects of genotype
and leucine are labeled as such, and asterisks denote differences between means following an
interaction with alpha set at p<0.05.
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Figure 5. mRNA analysis of markers of myogenesis in male and female mice as well as
plasma treated myotubes (A-P). Values are represented as means ± SEM. Main effects of
genotype and leucine are labeled as such, and asterisks denote differences between means
following an interaction with alpha set at p<0.05.
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Figure 6. Protein content of markers associated with protein anabolism in male and female
mice as well as plasma treated myotubes (A-P). Values are represented as means ± SEM.
Main effects of genotype and leucine are labeled as such, and asterisks denote differences
between means following an interaction with alpha set at p<0.05.
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Figure 7. mRNA abundance of markers of protein breakdown in male (A-B) and female mice
(D-E) as well as male (G-H) and female (J-K) plasma treated myotubes. Protein content of
ubiquitin in male and female mice (C & F) and male and female plasma treated myotubes (I
& L). Values are represented as means ± SEM. Main effects of genotype and leucine are
labeled as such, and asterisks denote differences between means following an interaction with
alpha set at p<0.05.
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Figure 8. Cross-sectional area of TA muscle in male and female mice (A-D). Myotube
diameter following addition of blood plasma from male and female mice (E-F). Values are
represented as means ± SEM. Main effects of genotype and leucine are labeled as such, and
asterisks denote differences between means following an interaction with alpha set at p<0.05.
alpha set at p<0.05.
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Abstract
Cancer cachexia is characterized by losses in lean body mass >5% and its progression
results in worsened quality of life and even outcomes in cancer patients. The chronic
inflammation and suppression of protein synthetic pathways have been researched extensively.
We reported mitochondrial degeneration preceded cancer cachexia development in male mice,
however no research to date has investigated the role and impact of fibrosis during the early
stages and development of cancer cachexia. The purpose of this study was to determine if
fibrosis occurs during cancer cachexia development, and to evaluate this in both sexes. 60 female
and 82 male C57BL/6J mice were injected with PBS or Lewis Lung Carcinoma at 8‐week age,
and tumors developed for 1, 2, 3, or 4 weeks to assess the time course of cancer cachexia
development. 3wk and 4wk female tumor‐bearing mice displayed a dichotomy in tumor growth
and were reassigned to high Tumor (HT) and low Tumor (LT) groups. in vivo analyses were also
performed on co-cultured C2C12 and 3T3 cells for skeletal muscle-ECM interactions in a
cachectic environment in vtiro. 4wk male and HT female mice displayed reduced tibialis anterior
and fat weight compared to PBS. Collagen deposition in skeletal muscle was increased at 1wk,
LT and HT in female and 4wk in male mice. MMP-9 was increased in HT and 4wk mice and
MMP-9 inhibitor, TIMP-1, was only decreased in female mice at 1wk, LT and HT. TGF-β was
elevated at 1wk and 4wk for female and male mice, respectively. 3T3 fibroblasts expressed
~350-500 more MMP-9 mRNA than C2C12 myotubes in vitro, and LCM treatment reduce the
relative amounts of Collagen 3 to 1 mRNA. These data present novel insights into fibrosis during
cancer cachexia development across both sexes.
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Introduction
Cancer cachexia is a progressive and involuntary wasting condition of lean body mass
that afflicts approximately 80% of all cancer patients and can be attributed to 20% of cancerassociated deaths (1, 2). Cancer cachexia is defined as losses in body mass >5% and this can be
accompanied with or without losses in adipose tissue (3, 4). To date, no singular method of
treatment has shown effective at eliminating cancer cachexia development due to the systemic
and complex nature of its underlying mechanisms (5-7). Further complicating research into
effective treatments for cancer cachexia is the emerging role of sexual dimorphism on cancer
cachexia progression, as recent studies have shown that males and females can differentially
respond to cancer cachexia (8-10). Metabolic and inflammatory instabilities are known
contributors to cancer cachexia progression and have been greatly researched (11, 12), but little
to none is known of the early role of fibrosis potentially plays on the development of cancer
cachexia.
Excessive fibrosis of healthy skeletal muscle has been shown to occur and worsen overall
outcomes in cancer patients (13). More so, unlike metabolic and inflammatory abnormalities that
can improve following cancer cessation, this fibrosis of vital and functional lean tissue is
irreversible and can affect patients throughout their lifespan (14). Transforming growth factor-β
(TGF-β) is a massive transcriptional activator of many cellular processes including the activation
of satellite cells as well as degradation and rearrangement of the extracellular matrix (ECM) that
surrounds skeletal muscle (15, 16). However, upregulation of TGF-β can result in excessive
ECM dysregulation and deposition of ECM components ultimately resulting in the replacement
of healthy skeletal muscle with non-contractile proteins such as collagens (17, 18). This
upregulation of TGF-β can be induced via its upstream regulator in Interleukin (IL)-6, an
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inflammatory marker which is commonly overexpressed in cachectic cancer patients (19). Taken
together, these data suggest that fibrosis in cancer patients is altered via TGF-β, and evaluation
of TGF-β and its downstream effectors could provide insights on fibrosis as it pertains to cancer
cachexia progression.
Males and females exhibit sexual dimorphism in skeletal muscle properties such as fiber
type composition within the same muscle, mitochondrial content, and number of satellite cells
innately, and this dimorphism is even documented in some muscle pathologies such as disuse
atrophy (10, 20). Differences in the relative amounts of circulating hormones like testosterone
and estrogen only adds to the complexity of the male and female phenotypic makeup within
skeletal muscle. For example, testosterone is typically higher in males and promotes muscle
protein synthesis and regeneration, while estrogen is typically higher in females and has a greater
impact on reducing inflammation (21, 22). Therefore, female mice could possess a greater
protective effect from inflammatory-based muscle wasting conditions such as cancer cachexia
when compared to males (10). Innate differences between sexes can therefore greatly affect
overall skeletal muscle health and even skeletal muscle health in pathologies such as cancer
cachexia (8, 10).
This study is the first to evaluate the role of fibrosis during the development of cancer
cachexia across both sexes. Implantation of Lewis Lung Carcinoma (LLC) cells allows for the
controlled development of cancer cachexia, and therefore a mechanistic analysis of fibrotic
pathways during this initial stage of cachexia. Evaluation of these fibrotic pathways could
elucidate potential avenues for therapeutic interventions aimed towards the prevention of fibrosis
and its contributions to cancer cachexia development. Therefore, the purpose of this study was to
utilize the implantation of LLC cells to analyze key regulators of the ECM in a controlled
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development of cancer cachexia. We hypothesized that the ECM and signaling pathways
involved in its modulation would be altered prior to cachexia. Herein this study we provide novel
evidence of altered fibrotic signaling coinciding with cancer cachexia development, however this
varied between sexes. These data highlight the emerging role of fibrosis on cancer cachexia even
in the earliest stages, and further strengthens the growing need for research in both males and
females as sex continues to create diverging responses to cancer cachexia and its underlying
mechanisms.
Methods
Animals and Interventions
All animal experiments were approved by the Institutional Animal Care and Use
Committee (IACUC) of the University of Arkansas, Fayetteville. Male and female C57BL/6J
mice were purchased from Jackson Laboratories. The mice were kept on a 12:12 h light–dark
cycle with ad libitum access to normal rodent chow and water. LLC cells (1 × 106) suspended in
100 μL sterile PBS were implanted to the hind flank of mice at 8 weeks of age as previously
described (23). The tumor was then allowed to develop for 1, 2, 3, or 4 weeks in separate
cohorts. For sham control, one group of mice received a bolus injection of 100 μL sterile PBS.
PBS controls were age-matched to the most cachectic group (4 weeks post-implantation,
12 weeks of age at tissue collection). In the female mice, there was a clear dichotomization
between the 3- and 4-weeks groups to cluster into smaller or larger tumor sizes. These 2 groups
were then isolated and split into low tumor (LT; ≤1.2g) and high tumor (HT; ≥2g) groups based
on this dichotomization of tumor size as denoted in Table 1 below. Animal tissues, organs, and
blood plasma were quickly collected under isoflurane anesthesia prior to euthanasia. Tissues
were weighed and snap-frozen in liquid nitrogen for further processing and stored at −80°C. The
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tibialis anterior muscle from males (TA) and plantaris muscle from females were submerged in
optimum cutting temperature compound (OCT) and then placed in liquid nitrogen cooled
isopentane. OCT mounted tissue was then stored at -80°C for histological analysis.
Lewis Lung Carcinoma and Implantation
LLC cells were prepared as described previously (23). LLC cells (ATCC CRL-1642)
were plated at passage 2. Cells were cultured in 250 ml culture flasks in DMEM supplemented
with 10% fetal bovine serum supplemented with 1% penicillin and streptomycin. Once cells
reached confluence, they were counted, trypsinized and diluted in PBS for implantation. Mice
were anesthetized with isoflurane and hair was removed from the right hind flank. LLC cells
(1x106) suspended in 100 µl sterile PBS and injected subcutaneously into the hind flank of mice
at 8 weeks of age as previously described (23). Tumors developed for up to 4 weeks.
Experimental endpoints were adjusted for signs of distress and veterinary recommendation for
humane care.
Myoblast and Fibroblast Co-Culture
C2C12 myoblast cells (ATCC CRL-1772) and 3T3 fibroblast cells (ATCC CRL-1658)
were co-cultured for an in vitro analysis of skeletal muscle to ECM interaction. C2C12 cells
were grown until they reached ~80% confluency at passage 2, where they were then transferred
to a 6-well plate and differentiated for 5 days. 3T3 fibroblast cells were then added via a
transwell-insert, which possesses a semi-permeable membrane, into the 6-well plate for creation
of a skeletal muscle to ECM connection in vitro. LLC conditioned media (LCM) or control
media were added to both cell types for 24hr, where they were then harvested for subsequent
RT-qPCR and Western Blot analysis.
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RNA Isolation, cDNA synthesis, and Quantitative Real-Time PCR
RNA isolation, cDNA synthesis, and quantitative real-time PCR were performed as we
have previously described (24-26). All targets were assayed using Taqman probes including: 18S
(Mm03928990_g1), Collagen 1 (Mm00801666_g1), Collagen 3 (Mm00802305_g1), MMP-2
(Mm00439498_m1), MMP-9 (Mm00439498_m1), Timp-1 (Mm01341361_m1), TGF-β1
(Mm01178820_m1), SMAD 2 (Mm00487530_m1), SMAD 3 (Mm01170760_m1). Taqman
probes were purchased from Applied Biosystems. RT-qPCR measured cycle threshold (Ct) and
the ΔCt value was calculated as the difference between the Ct value and the 18S Ct value. Final
quantification of mRNA abundance was calculated using the ΔΔCT method Ct =
[ΔCt(calibrator) – ΔCt(sample)]. Relative quantifications were then calculated as 2-ΔΔCt. 18S Ct
values were confirmed to not differ between experimental conditions for any comparison.
Immunoblotting
Immunoblotting was performed as we have previously described (27, 28). Protein
concentration and equal loading of SDS-page gels was determined via RC DC assayTM (BioRad), and target protein content was normalized to Ponceau S staining of 45kDa band.
Membranes were probed overnight for primary antibodies. Protein targets were purchased from
Cell Signaling Technology (CST) and selected based upon prior literature targeting key
components of ECM and fibrotic signaling pathways (29-33): β-Catenin (D10A8), PhosphoSMAD 2 (Ser465/467)/SMAD 3 (SerSMAD423/425) (D27F4), SMAD 2/3 (D7G7). Antibodies
were diluted in Tris-buffered saline, 0.1% Tween 20 with 5% milk. Membranes were imaged on
LiCor Odyssey FC using IR detection and images analyzed by LiCor Image StudioTM.
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Histology
TA and plantaris skeletal muscle stored in OCT were cryosectioned into 10μm thick
sections on polarized microscope slides. Muscle sections were then histologically stained with
Picro Sirius Red for quantification and analysis of overall collagen content within the muscle.
Cross-sections were also labeled with immunofluorescent antibodies for both Collagen 1 and
Collagen 3 for quantification and analysis of their relative amounts. Images were analyzed using
Nikon NIS Elements BR software package.
Statistical Analysis
Normality of data was established via a Shapiro Wilk test prior to any parametric
analysis. A one-way ANOVA was employed as the global analysis for each dependent variable
in both experiments. Where significance was detected, differences among means were
determined by a Student–Newman–Keuls post hoc test. For all experiments, α error rate was set
at 0.05 for all statistical tests. All data were analyzed using the Statistical Analysis System (SAS)
and figures were compiled using GraphPad Prism and data expressed as mean ± standard error of
the mean (SEM).
Results
Confirmation of Cachexia Development.
Measurements of body, skeletal muscle, organ and tissue weights are represented in
Table 1. Neither male nor female mice saw significant reductions in tumor-free body weight
compared to PBS controls (p>0.05), however both experienced reductions of tibialis anterior
muscle weight of ~11% and 15% in the HT and 4wk groups, respectively (p<0.05). Only males
saw a significant reduction in gastrocnemius weight of ~12% compared to PBS (p<0.05). Both
females and males had increases of ~33% and ~28% in liver weight and splenomegaly of ~395%
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and ~451% in the HT and 4wk groups compared to PBS, respectively (p<0.05). Fat weight also
decreased ~37% and ~35% for the HT and 4wk groups compared to PBS, respectively (p<0.05).
This data suggests cachectic losses in tibialis anterior muscle and fat mass, as well as cancer
associated increases in liver and spleen mass compared to control mice.
Excessive Deposition of Collagen in Skeletal Muscle
Picro Sirius Red staining of collagen within the plantaris and tibialis anterior muscle was
performed to determine overall fibrosis of both female and male mice skeletal muscle during the
development of cancer cachexia. 1wk and LT and HT female mice saw ~1.5-2% increases
(p<0.05) in the area of muscle that can be attributed as collagen compared to the PBS and 2wk
groups (Figure 1A). Male mice saw no significant increases in the relative area of collagen
within the muscle until 4 weeks post-injection with LLC where there was a ~3-fold increase
(p<0.05) in the percentage of collagen in the muscle compared to all other groups (Figure 1B).
ECM Components and Modifiers are Altered during Cancer Cachexia Development
1wk female mice displayed significant increases in Collagen 3 and 1 mRNA abundance
of ~0.7 and ~1.8-fold compared to all other groups, respectively (p<0.05; Figure 2A & 2B),
however the relative ratio of Collagen 3:1 mRNA abundance was decreased ~0.5-fold in 1wk
female mice compared to PBS (p<0.05; Figure 2C). Male mice saw no differences in Collagen 3
and 1 mRNA abundance (p>0.05 Figure 2D-F). MMP-2 mRNA abundance increased ~1-fold in
female mice at 1wk compared to the LT and HT groups (p<0.05; Figure 2G), and MMP-9
mRNA abundance increased ~2.5-fold in the HT group compared to PBS (p<0.05; Figure 2H).
TIMP-1, which binds and inhibits MMP-9 in its latent state, exhibited decreased mRNA
abundance ~0.7-fold in the 1wk, LT and HT groups compared to PBS in female mice (p<0.05;
Figure 2I). Male mice saw no changes in MM-2 and TIMP-1 mRNA abundance (p>0.05; 2J &
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2L) but saw a similar increase of ~2-fold in mRNA abundance of MMP-9 in the most cachectic
4wk group when compared to PBS (p<0.05; Figure 2K).
TGF-β-regulated Fibrosis during Cancer Cachexia Development
TGF-β1 mRNA abundance was increased ~1.2-fold at 1wk in female mice compared to
PBS (p<0.05; Figure 3A), and while there was a trend for SMAD 2 and 3 to exhibit similar
increased mRNA abundance there was ultimately no significance (p>0.05; Figure 3B & 3C).
There were no alterations in protein content for β-catenin or total SMAD 2/3 in female mice
(p>0.05; Figure 3D & 3E), and protein content for phosphorylate levels of SMAD 2/3 were not
detectable (ND). TGF-β1 mRNA abundance increased ~0.5-fold in 4wk male mice compared to
PBS (p<0.05; Figure 3F), but there were no differences or trends detected in mRNA abundance
of SMAD 2 and 3 (p>0.05; Figure 3G & 3H). Male mice also saw no differences in protein
content of β-catenin and SMAD 2 and 3 (p>0.05; Figure 3I & 3J) and phosphorylated SMAD 2
and 3 were ND similar to female mice.
Major Collagens within Skeletal Muscle Fluctuate during Cancer Cachexia Development
The relative ratios of collagens 3 and 1 were measured via immunofluorescent labeling to
observe variations of the major proteins that constitute the ECM during cancer cachexia
development. The amount of collagen 3 to collagen 1 present in the TA muscle of male mice
decreased ~1-fold at 1wk and 3wk compared to PBS (p<0.05; Figure 4A).
in vitro Analysis of Skeletal Muscle-ECM Dynamics in a Cachectic Environment
There was a main effect of C2C12 myotubes cells to have ~0.5-fold greater mRNA
abundance of TGF-β1 compared to 3T3 fibroblasts (p<0.05; Figure 5A). There was a main effect
of myotubes to have ~4-fold less Collagen 1 mRNA abundance, and a main effect of LCM
treatment to reduce Collagen 1 mRNA abundance across both cell types (p<0.05; Figure 5B).
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There were main effects for myotubes to have ~0.8-fold greater Collagen 3:1 ratio of mRNA
abundance and for LCM treatment to increase this ratio as well (p<0.05; Figure 3C). There were
no differences in mRNA abundance of MMP-2 in either myotubes or 3T3 cells (p>0.05; Figure
3D), however mRNA abundance of MMP-9 was ~450-fold greater in 3T3 cells than in myotubes
and LCM treatment reduced MMP-9 mRNA ~200-fold in 3T3 cells compared to Vehicle
(p<0.05; Figure 3E). There was a main effect for 3T3 cells to have decreases mRNA abundance
of TIMP-1 by ~0.6-fold compared to C2C12 cells (p<0.05; Figure 3F). No differences were
observed in C2C12 or 3T3 cells for protein content of phosphorylated-total SMAD 2/3 and βcatenin (p>0.05; Figure 3G & 3H). Myotube diameter was reduced ~4μM following treatment
with LCM compared to Vehicle (p<0.05; Figure 3I).
Discussion
In this study, we are the first to evaluate and report variations in fibrosis and associated
markers during the development of cancer cachexia in both sexes. Our analysis consisted of
major ECM components such as collagens, MMPs and TIMPs involved with breakdown and
remodeling of the ECM, and a key signaling pathway associated with fibrosis across pathologies
in TGF-β and its downstream effectors. These key markers of fibrosis were analyzed in vivo and
in vitro to create a comprehensive approach to understanding if the ECM is altered during the
development of cancer cachexia, and if so, what are the likely contributors to the result. While no
direct comparisons can be made between males and females, there appears to be differences in
the timing of increased fibrosis of the skeletal muscle as cancer cachexia begins to develop.
Female mice saw significant alterations in collagen content, collagen mRNA, TIMP-1 mRNA,
and TGF-β mRNA as early as 1wk post-injection with LLC cells (Figures 1-3). Male mice on the
other hand displayed no significance in fibrosis or fibrosis-related markers until 4wk almost
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across the board, with the sole exception of Collagen 3:1 being decreased ~1-fold following
immunofluorescent labeling (Figure 4). in vitro co-culturing of myotubes and fibroblast cells in a
cachectic environment yielded interesting findings, albeit in the absence of sex distinctions, but
with the added distinction of isolating muscle and ECM associated cell lines (Figure 5). Of note,
both C2C12 and 3T3 cells had higher/lower relative mRNA abundance in certain collagen,
MMPs, and TIMP-1 relative to one another. Addition of LCM did indeed reduce myotube
diameter significantly as well as reduce Collagen 1 mRNA and increase Collagen 3:1 mRNA in
both cell types. These findings support the growing theme across literature for divergent
responses to myopathologies between male and female sexes as well as reinforce the need for
these sex-based comparisons in future studies (8, 35, 36).
As reported by Lim et al. (34), the dichotomization of tumor burden observed in the
female mice supports the correlation with overall tumor burden to development of cancer
cachexia. However, with regards to incidence of fibrosis, we observed increased collagen content
and alterations in ECM components and regulators as early as 1wk in female mice. This
observation indicates that while tumor burden still is tightly correlated to cancer cachexia in both
sexes, the early stages of fibrotic development as it pertains to cancer cachexia is not as tightly
correlated to overall tumor burden. Male mice didn’t observe the same early stages alterations
outside of a decrease in Collagen 3:1 at 1wk in male (Figure 4). These data suggest that both
males and females experience alterations in their ECM as early as 1wk post-injection with LLC
cells, but not with complete consistency across the associated regulators in MMPs, TIMP-1, and
TGF-β. Recent studies report reductions in TGF-β mRNA in cardiac muscle in a Colon
adenocarcinoma cells 26 (CT26) model of cancer cachexia (37) and increased TGF-β mRNA in
adipose and skeletal muscle tissue in models of pancreatic cancer cachexia (13, 38), but all
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studies exhibit increased fibrosis. TGF-β then appears to be a clear and consistent regulator of
fibrosis in cancer cachexia, and our findings suggest its role can even precede development, at
least in female mice.
The role of TGF-β in fibrosis across pathologies has been well documented (39-41). The
canonical pathway of TGF-β is to activate its downstream regulators in SMAD 2 and 3, which in
turn can induce expression of collagens such as Collagen 1 and 3 (40). Dysregulations in TGF-β
leads to improper deposition of ECM components via SMAD 2 and 3, ultimately resulting in
fibrosis. However, here we report no significant alterations in SMAD 2 and 3 mRNA or protein
content in either male or female mice or even in vitro following addition of LCM (Figure 3). We
also measured β-catenin content, which resulted in no differences as well, as cross-talk between
TGF-β and the Wnt/β-catenin pathway has been noted in previous literature (42-45). The lack of
SMAD 2 and 3 or β-catenin induction appears to suggest a non-canonical pathway is involved in
regulation of the ECM and its components in this model of cancer cachexia. However, what
pathway(s) is/are involved remains unclear and requires further research.
Our final experiment aimed to isolate the mechanistic interaction between skeletal muscle
and the ECM at a cellular level. To do so, we co-cultured C2C12 myotubes with 3T3 fibroblasts
in vitro and then created a cachectic environment via addition of LCM. We then analyzed the
same key components and regulators of the ECM and fibrotic pathways that were targeted in the
in vivo approach (Figure 5). One major overall finding was the discrepancies in relative mRNA
abundance between the myotube and fibroblast cells across the various markers. Of particular
interest was the stark contrast observed in MMP-9 abundance, where fibroblast cells exhibited
upwards of ~500-fold greater amounts of MMP-9 mRNA. Several recent studies have linked
MMP-9 secretion not only to increased fibrosis, but more specifically to enhanced tumor growth
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and formation (46, 47). LCM addition increased Collagen 3:1 mRNA abundance in both cell
types as well as decreased MMP-9 mRNA in fibroblast cells by ~200-fold, however LCM
addition had no effect on any other markers of fibrosis.
In summary, this study set out to obtain a better understanding of fibrosis during the very
early stages and development of cancer cachexia in both sexes. The findings we report support
the growing trend for females and males to display divergent responses to pathologies. While
both sexes displayed increased fibrosis at their heaviest tumor burden compared to controls,
females uniquely exhibited alterations to markers associated with fibrosis and ECM regulation as
early as 1wk post-injection with LLC. Due to both sexes possessing increases in collagen
deposition at the onset of cancer cachexia, it appears that fibrosis plays a role in the development
of cancer cachexia as well as its well-noted progression (13,). Overall, increased fibrosis is
involved with the development of cancer cachexia and males and females seemingly differ in the
timing of alterations in the relevant fibrosis-related markers. However, more research is
necessary to ascertain the players involved in the elevated collagen deposition and fibrosis
shown in our results as TGF-β was elevated but the traditional downstream effectors in SMADs
2 and 3 and β-catenin were unchanged. A greater understanding of these pathways involved with
fibrosis development during the pre- and early-stage development of cancer cachexia could point
to potential therapeutic avenues and improve overall patient outcomes.
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Figure Legends
Table 1. Descriptive Measurements
Body weight, tumor weight, hindlimb skeletal muscle weight, organ and tissue weights of PBS
and LLC-injected C57BL6/J mice. Values are represented as means ± SEM with significance set
at p<0.05. Different letters signify differences in group means following a significant F-test and
Tukey’s post-hoc analysis. Female data reported in Lim et al. 2021 (34), and male data as
reported in Brown et al. 2017 (23).
Figure 1. Collagen Content in Muscle
Collagen deposition within skeletal muscle measured via Picro Sirius Red staining of overall
collagen in the plantaris (female) and tibialis anterior muscle (male). Values are represented as
means ± SEM with significance set at p<0.05. Different letters signify differences in group
means following a significant F-test and Tukey’s post-hoc analysis.
Figure 2. ECM Remodeling Regulators
Relative mRNA abundance of major collagen types, MMPs and TIMPs within the tibialis
anterior muscle. Values are represented as means ± SEM with significance set at p<0.05.
Different letters signify differences in group means following a significant F-test and Tukey’s
post-hoc analysis.
Figure 3. Fibrotic Pathways
Relative mRNA abundance of TGF-β1, SMAD 2 and 3 as well as protein levels of β-catenin and
SMAD 2 and 3 within the tibialis anterior muscle. Values are represented as means ± SEM with
significance set at p<0.05. Different letters signify differences in group means following a
significant F-test and Tukey’s post-hoc analysis.
Figure 4. Immunofluorescence of Collagens 3 and 1
Ratio of collagen 3 to 1 in the tibialis anterior muscle following immunofluorescent labeling.
Values are represented as means ± SEM with significance set at p<0.05. Different letters signify
differences in group means following a significant F-test and Tukey’s post-hoc analysis.
Figure 5. in vitro Analysis of Fibrosis
Relative mRNA abundance of collagens, MMPs, and TIMP-1 as well as protein levels of SMAD
2 and 3 and β-catenin from Vehicle and LCM treated C2C12 myotubes and 3T3 fibroblasts.
Myotube diameter of differentiated C2C12 cells was also calculated following addition of LCM.
Values are represented as means ± SEM with significance set at p<0.05.
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Figures

Table 1. Body weight, tumor weight, hindlimb skeletal muscle weight, organ and tissue
weights of PBS and LLC-injected C57BL6/J mice. Values are represented as means ± SEM
with significance set at p<0.05. Different letters signify differences in group means following
a significant F-test and Tukey’s post-hoc analysis. Female data reported in Lim et al. 2021
(34), and male data as reported in Brown et al. 2017 (23).
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Figure 1. Collagen deposition within skeletal muscle measured via Picro Sirius Red staining
of overall collagen in the plantaris (female) and tibialis anterior muscle (male). Values are
represented as means ± SEM with significance set at p<0.05. Different letters signify
differences in group means following a significant F-test and Tukey’s post-hoc analysis.
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Figure 2. Relative mRNA abundance of major collagen types, MMPs and TIMPs within the
tibialis anterior muscle. Values are represented as means ± SEM with significance set at
p<0.05. Different letters signify differences in group means following a significant F-test and
Tukey’s post-hoc analysis.
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Figure 3. Relative mRNA abundance of TGF-β1, SMAD 2 and 3 as well as protein levels of
β-catenin and SMAD 2 and 3 within the tibialis anterior muscle. Values are represented as
means ± SEM with significance set at p<0.05. Different letters signify differences in group
means following a significant F-test and Tukey’s post-hoc analysis.
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Figure 4. Ratio of collagen 3 to 1 in the tibialis anterior muscle following immunofluorescent
labeling. Values are represented as means ± SEM with significance set at p<0.05. Different
letters signify differences in group means following a significant F-test and Tukey’s post-hoc
analysis.
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Figure 5. Relative mRNA abundance of collagens, MMPs, and TIMP-1 as well as protein
levels of SMAD 2 and 3 and β-catenin from Vehicle and LCM treated C2C12 myotubes and
3T3 fibroblasts. Myotube diameter of differentiated C2C12 cells was also calculated
following addition of LCM. Values are represented as means ± SEM with significance set at
p<0.05.
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Chapter 5
Overall Discussion
In this dissertation I examined sexual dimorphism of cancer cachexia in two different
models of cancer cachexia in LLC and APCMin/+ mice. One model focused on the role of fibrosis
during the stages before and up to the development of cancer cachexia, and the second model
focused on the effects of leucine supplementation on cancer cachexia progression. The data
presented strongly support the emerging trend for sexual dimorphism in cancer cachexia across
various models, and therefore the growing need for inclusion of both sexes in future studies.
Here I show increased fibrosis in both sexes as cachexia develops at 4wks post-injection with
LLC but with female mice exhibiting earlier inductions in TGF-β in males. I also show
exacerbated losses in body weight in male APCMin/+ mice following supplementation with
leucine and this effect was not observed in female APCMin/+ mice.
Future studies in both models should focus on elucidating the underlying pathways
involved in the dimorphic sexual response. LLC males and females saw initial increases in TGFβ at different timepoints, and the typically understood downstream effectors in SMAD 2 and 3 as
well β-catenin were unaffected in both sexes. The losses in body weight observed in male
APCMin/+ mice was not accompanied by greater reductions in any muscle weights, and more
importantly not uniquely accompanied by upregulation of any markers of proteolysis or protein
anabolism inhibition.
Fibrosis Occurs during the Development of Cancer Cachexia in Both Male and Females
In this study I analyzed collagen content and markers associated with fibrosis in both
sexes following cancer implantation up to the development of cancer cachexia. Based on our
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data both males and females exhibit fibrosis as cancer cachexia develops. However, females saw
alterations in TGF-β as early as 1wk post-injection with LLC whereas males saw no increase
until 4wks. As SMAD 2 and 3 as well as β-catenin did not alter as cancer cachexia developed it
appears that a non-canonical pathway could be involved in these early stages of fibrosis.
Although, it is important to note the early increases in TGF-β were accompanied with increases
in collagen 3 and 1 mRNA and overall collagen content with actual muscle tissue. These data
suggest females experience earlier alterations in fibrosis during cancer cachexia development
compared to males.
Leucine Supplementation Exacerbates Cancer Cachexia in Males but Not Females
To my knowledge I am the first to report greater sex-dependent losses in body weight in
cancer cachexia following leucine supplementation. These losses in body weight observed in
male APCMin/+ mice was accompanied with higher IL-6 mRNA abundance, and interestingly not
also with higher NFκB or TNF-α. In fact, myotubes treated with male APC L plasma saw
decreases in TNF-α specifically. Female mice uniquely displayed elevation of MyoD mRNA in
APCMin/+ mice as well as decreases in Pax7 mRNA in APC L plasma treated myotubes. These
shifts in markers of satellite cell dynamics to favor proliferation and differentiation could point to
enhanced muscle regeneration and an overall protective effect of skeletal muscle not observed in
male mice. The potentiality of this female protective effect is further supported when myotube
diameter was measured, as only the male APCMin/+ plasma treated myotubes experienced
reductions in diameter.

105

Concluding Statements
These studies show novel evidence for sex differences in two separate models of cancer
cachexia. Males and females can possess inherent variations in responses to both interventions
and pathologies, and a lack of evaluation of both sexes in future studies does not set up future
clinical treatments up for success.
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